<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" id="d221712278" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><self-uri>pubs.acs.org/molecularpharmaceutics</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12135038</article-id><article-id pub-id-type="pmcid-ver">PMC12135038.1</article-id><article-id pub-id-type="pmcaid">12135038</article-id><article-id pub-id-type="pmcaiid">12135038</article-id><article-id pub-id-type="pmid">40310503</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00254</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Enantiomeric
Excess Bupivacaine in a Lavender Oil
NLC Tested in a Melanoma Model: Prolonged Release and Anticancer Effect</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7192330</contrib-id><name name-style="western"><surname>Geronimo</surname><given-names initials="G">Gabriela</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6309727</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7377-8532</contrib-id><name name-style="western"><surname>Rodrigues da Silva</surname><given-names initials="GH">Gustavo H.</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7038053</contrib-id><name name-style="western"><surname>de Moura</surname><given-names initials="LD">Ludmilla D.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7192335</contrib-id><name name-style="western"><surname>de Carvalho</surname><given-names initials="FV">Fab&#237;ola V.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7192341</contrib-id><name name-style="western"><surname>Mendon&#231;a</surname><given-names initials="TC">Talita C.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7192347</contrib-id><name name-style="western"><surname>Olivo</surname><given-names initials="LB">Laura B.</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6214312</contrib-id><name name-style="western"><surname>Verlindo de Ara&#250;jo</surname><given-names initials="B">Bibiana</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6214313</contrib-id><name name-style="western"><surname>Dalla Costa</surname><given-names initials="TC">Teresa C.</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7192349</contrib-id><name name-style="western"><surname>Lavareze</surname><given-names initials="L">Luccas</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7192351</contrib-id><name name-style="western"><surname>Mariano</surname><given-names initials="FV">Fernanda V.</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">87076</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4504-5723</contrib-id><name name-style="western"><surname>de Paula</surname><given-names initials="E">Eneida</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Biochemistry and Tissue Biology</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">28132</institution-id><institution>Institute
of Biology, University of Campinas&#58872;UNICAMP</institution></institution-wrap>, <city>Campinas</city>, <state>SP</state>
<postal-code>13083-862</postal-code>, <country>Brazil</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution>Brazilian
Biosciences National Laboratory, Brazilian Center for Research in
Energy and Materials</institution>, <city>Campinas</city>, <state>SP</state>
<postal-code>13083-970</postal-code>, <country>Brazil</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Pharmaceutical
Sciences Graduate Program, Faculty of Pharmacy</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">28124</institution-id><institution>Federal University of Rio Grande do Sul&#58872;UFRGS</institution></institution-wrap>, <city>Porto Alegre</city>, <state>RS</state>
<postal-code>90610-000</postal-code>, <country>Brazil</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Department
of Pathology, Faculty of Medical Sciences</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">67791</institution-id><institution>UNICAMP</institution></institution-wrap>, <city>Campinas</city>, <state>SP</state>
<postal-code>13083-888</postal-code>, <country>Brazil</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>depaula@unicamp.br</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>gustavo.rsilva@lnbio.cnpem.br</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>01</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>02</day><month>6</month><year>2025</year></pub-date><volume>22</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">489873</issue-id><fpage>3351</fpage><lpage>3365</lpage><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>4</month><year>2025</year></date><date date-type="online"><day>01</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-05 11:25:42.047"><day>05</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-05-01"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-05-01">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="mp5c00254.pdf"/><abstract><p>Recent studies have highlighted the potential of local
anesthetics
(LA) as adjuvants in cancer treatment, specifically by increasing
survival rates when used in surgical excisions. However, the clinical
use of LA is restricted due to their systemic toxicity. The development
of drug delivery systems could address this issue and advance the
utilization of these molecules. In this research, we explored the
pharmacokinetics (using microdialysis probes) and antitumor properties
of a nanostructured lipid carrier (NLC) formulation containing the
commercially available enantiomeric excess form of bupivacaine (BVC<sub>S75</sub>). This NLC was prepared with lavender oil (NLC-L-BVC),
an excipient with inherent antitumor properties. We compared this
formulation to a control (NLC-BVC) using synthetic lipids. Pharmacokinetic
assessments of the NLCs confirmed the sustained release of BVC<sub>S75</sub> within the tumor, characterized by a reduced elimination
rate constant and longer half-life (&#8764;6&#215;). The encapsulation
of BVC<sub>S75</sub> within nanoparticles (whether natural or synthetic)
enhanced its effectiveness in treating the primary tumor, resulting
in the inhibition of tumor growth (70% with NLC-L-BVC and 72% with
NLC-BVC), outperforming free BVC (17% inhibition). However, the association
of lavender oil with BVC<sub>S75</sub> in an NLC did not yield synergistic
properties. Furthermore, all BVC<sub>S75</sub> treatments (whether
free or encapsulated) improved animal survival rates. These findings
confirm that encapsulation of bupivacaine in NLC can prolong drug
action at the local site, contributing to improved local antitumor
therapy while mitigating systemic effects.</p></abstract><abstract abstract-type="graphical"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="agr1" position="float" orientation="portrait" xlink:href="mp5c00254_0012.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="tgr1" position="float" orientation="portrait" xlink:href="mp5c00254_0010.jpg"/></abstract><kwd-group><kwd>nanostructured lipid carriers</kwd><kwd>drug delivery</kwd><kwd>bupivacaine</kwd><kwd>melanoma</kwd><kwd>lavender oil</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100001807</institution-id></institution-wrap></funding-source><award-id>2019/17784-0</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100001807</institution-id></institution-wrap></funding-source><award-id>2021/02575-7</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100002322</institution-id></institution-wrap></funding-source><award-id>130258/2021-0</award-id></award-group></funding-group><funding-group><award-group id="fnd-4"><funding-source><institution-wrap><institution>Funda??o de Amparo ? Pesquisa do Estado do Rio Grande do Sul</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004263</institution-id></institution-wrap></funding-source><award-id>19/2551-000278-6</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp5c00254</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp5c00254</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>5da57db7cdffbf7d181b47d38263b74f08962323ca781f0f77f840276180e3f8</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Local anesthetics (LA)
are drugs that reversibly inhibit the conduction
of nerve impulses, resulting in complete analgesia and motor blockade.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> These molecules have an established use in clinical and surgical
procedures, aiding in the management of acute pain and inflammation.<xref rid="ref3" ref-type="bibr"/> However, an accumulating body of evidence suggests
that different classes of anesthetics can elicit either pro- or antimetastatic
effects, depending on the type of cancer cell, dosage, and administration
protocol.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>&#8722;<xref rid="ref4" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content> By evaluating LA mechanisms of action in tumor cells, therapists
can establish methodologies for selecting an anesthetic strategy and
clinical regimen with the best antitumor properties and increased
patient survival.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>&#8722;<xref rid="ref8" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref9" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref10" ref-type="bibr"/>
</named-content> In clinical cancer treatment, the adjuvant effect of LA is linked
to their immunomodulatory action, which enhances antitumor immunity
by reducing pro-inflammatory cytokines and stress hormones.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref11" ref-type="bibr"/>
</named-content> Furthermore, LA help minimize surgical inflammation and establish
an unfavorable environment for tumor proliferation.<xref rid="ref12" ref-type="bibr"/>
</p><p>Recent reports have unveiled that lidocaine, a local
anesthetic
(LA) from the aminoamide family, has antineoplastic properties akin
to oncology treatments when directly applied to malignant lesions,<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> affecting the viability, migration, and invasiveness of cancer cells.,<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> Indeed, preclinical studies have
demonstrated that aminoamide LA exhibit antiproliferative, antimetastatic,
and pro-apoptotic activities in various types of tumor cells<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>
</named-content> through mechanisms such as the
suppression of protein translation, cytoskeletal remodeling, autophagy
induction, cell cycle arrest, aerobic glycolysis rate reduction, and
increased expression of caspase-3.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>&#8722;<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr"/>
</named-content> These interconnected mechanisms
through different pathways collectively contribute to the induction
of cancer cell apoptosis.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref11" ref-type="bibr"/>
</named-content>
</p><p>Bupivacaine (BVC) is a
long-acting aminoamide LA widely used in
prolonged surgical procedures,<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>,<xref rid="ref19" ref-type="bibr"/>
</named-content> although its cardiotoxicity
is also well-documented in clinical practice.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>&#8722;<xref rid="ref21" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref22" ref-type="bibr"/>
</named-content> Due to the
chiral carbon present in its piperidine ring, BVC is a racemic mixture,
of which the levorotatory form, S(&#8722;), has a lower degree of
toxicity to the cardiovascular and central nervous systems, while
the dextrorotatory, R&#173;(+), form is more potent.<named-content content-type="bibref-group">
<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref24" ref-type="bibr"/>
</named-content> This is due to the stereoselectivity of its enantiomers, where the
R&#173;(+) isomer exhibits greater binding to the cardiac Na channel than
the S(&#8722;) isomer, increasing the propensity for cardiotoxicity,
as already explored in many studies.<named-content content-type="bibref-group">
<xref rid="ref25" ref-type="bibr"/>&#8722;<xref rid="ref26" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref27" ref-type="bibr"/>
</named-content> This fact has led to
the stereoselective chemical synthesis of an enantiomeric mixture
that contains 75% and 25%, respectively, of the S(&#8722;) and R&#173;(+)
BVC isomers (BVC<sub>S75</sub>, commercialized as Novabupi). Due to
its lower affinity for sodium, potassium, and calcium channels than
the commercial racemic mixture, BVC<sub>S75</sub> exhibits reduced
arrhythmogenesis and neurotoxicity, resulting in lower toxicity to
the central nervous and cardiac systems<named-content content-type="bibref-group">
<xref rid="ref28" ref-type="bibr"/>,<xref rid="ref29" ref-type="bibr"/>
</named-content> and providing
a greater safety margin.<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>,<xref rid="ref30" ref-type="bibr"/>
</named-content>
</p><p>The effects of
BVC on various melanoma cell lines have been reported,
including reduced cell survival, disruption of cytoskeletal organization,
impairment of energetic metabolism, and the inhibition of cell proliferation
and pulmonary metastasis.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref31" ref-type="bibr"/>
</named-content> In other tumor types, BVC induces apoptosis via caspase-dependent
and caspase-independent pathways,<named-content content-type="bibref-group">
<xref rid="ref32" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content> the production
of reactive oxygen species (ROS) through the activation of AMP-induced
protein kinase (AMPK),<xref rid="ref34" ref-type="bibr"/> and inhibition
of cell proliferation and metastasis by suppressing PI3K/Akt and MAPK
signaling pathways.<xref rid="ref35" ref-type="bibr"/> However, to our knowledge,
no <italic toggle="yes">in vivo</italic> investigation has been carried out for
bupivacaine or its stereoisomers to confirm their antiproliferative
effect in an entire organism.</p><p>A second generation of lipid-based
DDS, the nanostructured lipid
carriers (NLCs), emerged in the last decade of the 20th century.<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>,<xref rid="ref37" ref-type="bibr"/>
</named-content> These nanoparticles exhibit an internal architecture composed of
a blend of solid and liquid lipids stabilized by surfactants. The
blend reduces the crystallinity of the matrix, increasing their upload
capacities and preventing premature release during storage.<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>&#8722;<xref rid="ref37" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref38" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref39" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref40" ref-type="bibr"/>
</named-content> NLCs are a valuable tool for modulating biodistribution, decreasing
systemic toxicity, and maximizing the concentration of active pharmaceutical
ingredients in the target tissue.<named-content content-type="bibref-group">
<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>
</named-content> Consequently, NLCs may be used to increase the efficacy
of antineoplastics in cancer treatment while decreasing their toxic
effects.<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>,<xref rid="ref38" ref-type="bibr"/>,<xref rid="ref41" ref-type="bibr"/>
</named-content> In this regard,
the encapsulation of LA in NLCs can enhance their antimetastatic and
pro-apoptotic properties by prolonging their local action time, enhancing
their antitumoral potential and reducing their systemic effects.</p><p>Moreover, NLCs can be prepared with functional excipients, such
as natural lipids (waxes, essential oils), which add their intrinsic
pharmaceutical properties to the formulation.<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>&#8722;<xref rid="ref42" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref43" ref-type="bibr"/>
</named-content> In this context,
we decided to use lavender essential oil (LO) as a functional excipient
in an NLC to promote a synergistic effect with BVCS75. LO contains
monoterpenes, such as linalyl acetate (28.6%), linalool (27.7%), eucalyptol,
terpinen-4-ol (5.0%), caryophilene (3.9%), and lavandulyl acetate
(3.7%). Therapeutic actions have been reported for these monoterpenes,<named-content content-type="bibref-group">
<xref rid="ref44" ref-type="bibr"/>&#8722;<xref rid="ref45" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref46" ref-type="bibr"/>
</named-content> such as sedative, antidepressant, antimicrobial, antifungal, antioxidant,
and antineoplastic effects.<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>&#8722;<xref rid="ref46" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref47" ref-type="bibr"/>
</named-content> Linalyl acetate, for instance,
can inhibit melanogenesis in melanoma cells through oxidative stress
by reducing tyrosine kinase activity through the regulation of JNK
and ERK signaling pathways, promoting increased sensitivity to the
cytotoxic action of chemotherapeutic agents in tumor cells.<named-content content-type="bibref-group">
<xref rid="ref47" ref-type="bibr"/>&#8722;<xref rid="ref48" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref49" ref-type="bibr"/>
</named-content> The activity of such LO components has also been reported in various
human tumor cell lines in culture: neuroblastoma (SHSY5Y), breast
adenocarcinoma (MCF-7), colorectal adenocarcinoma (Caco2), and lymphoblastic
leukemia (CCRF-CEM).<xref rid="ref50" ref-type="bibr"/>
</p><p>Several preclinical
trials have investigated the effects of LA
on metastasis control and tumor regression in animal models.<named-content content-type="bibref-group">
<xref rid="ref51" ref-type="bibr"/>&#8722;<xref rid="ref52" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref53" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref54" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref55" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref56" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref57" ref-type="bibr"/>
</named-content> However, the antitumor action of bupivacaine encapsulated in a delivery
system within melanoma cells remains to be clarified. In light of
this, we employed a primary melanoma induction model.<xref rid="ref58" ref-type="bibr"/> Melanoma is the most lethal form of skin cancer, accounting
for 73% of global deaths caused by cutaneous cancer.<xref rid="ref59" ref-type="bibr"/> Its severity can be attributed to the tumor&#8217;s notable
propensity for invasion, metastasis, heterogeneity, and therapeutic
resistance, facilitating its aggressive behavior.<xref rid="ref4" ref-type="bibr"/> The gold standard for treating primary melanoma involves
wide excision, with margins determined by the tumor&#8217;s thickness,<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref60" ref-type="bibr"/>
</named-content> in which the use of LA is common.<xref rid="ref61" ref-type="bibr"/>
</p><p>This work describes a potential therapeutic and innovative approach
to improve LA efficacy in onco-anesthesia, utilizing BVC<sub>S75</sub> encapsulated in an NLC composed of various (natural and synthetic)
excipients in the treatment of melanoma. We present the results of
local pharmacokinetic and efficacy studies to evaluate this nanometric
system&#8217;s effectiveness.</p></sec><sec id="sec2"><label>2</label><title>Materials and Methods</title><sec id="sec2.1"><label>2.1</label><title>Materials</title><p>Enantiomeric excess, 75:25
S(&#8722;):R&#173;(+) mol % bupivacaine hydrochloride (BVC<sub>S75</sub>) was donated by Crist&#225;lia Prod. Quim. Farm. Ltd. (Itapira,
SP, Brazil). The natural products beeswax (BW) and lavender oil (LO)
were purchased from Imp&#233;rio das Ess&#234;ncias (S&#227;o
Paulo, SP, Brazil) and Terra Flor Aromaterapia (Alto Para&#237;so
de Goi&#225;s, GO, Brazil), respectively. Cetyl palmitate was purchased
from Dhaymers Qu&#237;mica Fina (Brazil), and Capryol 90 was donated
by Gattefoss&#233; (France). Pluronic F68 (P68), Dulbecco&#8217;s
modified Eagle&#8217;s medium (DMEM), fetal bovine serum, penicillin,
and streptomycin were purchased from Sigma-Aldrich (St Louis, MO,
USA). Deionized water (18 M&#937;) was obtained with an Elga USF
Maxima ultrapure water purifier (Elga Lab Water, High Wycombe, UK).
American Type Culture Collection (ATCC, Manassas, VA, USA) provided
murine melanoma (B16&#8211;F10 lineage). All other reagents were
of analytical grade.</p></sec><sec id="sec2.2"><label>2.2</label><title>NLC Preparation</title><p>NLC formulations
were prepared using the emulsification-ultrasonication method.<xref rid="ref62" ref-type="bibr"/> BVC<sub>S75</sub> was added to the lipid phase,
composed of LO and BW, which was heated to 60 &#176;C until complete
solubilization. Simultaneously, an aqueous phase composed of P68 surfactant
solution was heated to the same temperature, and both phases were
mixed under high-speed agitation (11,000 rpm) for 3 min in an Ultra-Turrax
homogenizer (IKA Werke, Staufen, Germany). The mixture was then tip-sonicated
for 16 min in a Vibracell (Sonics &amp; Mat. Inc., Danbury, CT, USA)
sonicator at 60 W and 20 kHz, in alternating 30 s (on/off) cycles
to avoid overheating the sample. Immediately afterward, the sample
was cooled to room temperature in an ice bath to form nanoparticles
(NLC-L-BVC); a blank formulation (NLC-L) without the anesthetic was
also prepared.</p><p>For the sake of comparison, a second formulation
(NLC-BVC) was prepared to clarify the effect of the excipient LO in
the <italic toggle="yes">in vivo</italic> antineoplastic effect of the nanoparticles. <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> shows the composition
of the NLC formulations.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Composition of the Optimized (Natural
and Synthetic) NLC Formulations Used in This Study</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">Lipid matrix</th><th align="center" colspan="1" rowspan="1">Formulation</th><th align="center" colspan="1" rowspan="1">Solid lipid</th><th align="center" char="." colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Liquid lipid</th><th align="center" char="." colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Surfactant</th><th align="center" colspan="1" rowspan="1">%</th><th align="center" char="." colspan="1" rowspan="1">BVC<sub>S75</sub> (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Natural</td><td align="left" colspan="1" rowspan="1">NLC-L</td><td align="left" colspan="1" rowspan="1">Beeswax</td><td align="char" char="." colspan="1" rowspan="1">10.5</td><td align="left" colspan="1" rowspan="1">Lavender oil</td><td align="char" char="." colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">Pluronic
F-68</td><td align="left" colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Natural</td><td align="left" colspan="1" rowspan="1">NLC-L-BVC</td><td align="left" colspan="1" rowspan="1">Beeswax</td><td align="char" char="." colspan="1" rowspan="1">10.5</td><td align="left" colspan="1" rowspan="1">Lavender oil</td><td align="char" char="." colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">Pluronic F-68</td><td align="left" colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Synthetic</td><td align="left" colspan="1" rowspan="1">NLC-BVC</td><td align="left" colspan="1" rowspan="1">Cetyl palmitate</td><td align="char" char="." colspan="1" rowspan="1">9.0</td><td align="left" colspan="1" rowspan="1">Capryol 90</td><td align="char" char="." colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">Pluronic F-68</td><td align="left" colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">0.5</td></tr></tbody></table></table-wrap></sec><sec id="sec2.3"><label>2.3</label><title>
<italic toggle="yes">In Vivo</italic> Studies</title><sec id="sec2.3.1"><label>2.3.1</label><title>Animals</title><p>Female adult C57BL/6J mice
aged 6&#8211;8 weeks (18&#8211;22 g) were obtained from the Multidisciplinary
Center for Biological Research (CEMIB-UNICAMP). The experimental protocols
were approved by the UNICAMP Institutional Animal Care and Use Committee
(#5736-1/2021 and 5940-1/2022) that strictly follows the guidelines
of the National Committee of Animal Experimentation (CONCEA, Bras&#237;lia,
DF, Brazil). The animals were housed at 25 &#177; 2 &#176;C, 30&#8211;70%
humidity, and under 12/12 h light/dark cycles, with food and water
available <italic toggle="yes">ad libitum</italic>.</p></sec><sec id="sec2.3.2"><label>2.3.2</label><title>Tumor Cell Inoculation</title><p>After the
animals were intraperitoneally anesthetized with ketamine (100 mg/kg)
and xylazine (10 mg/kg), they received aliquots (60 &#956;L) of 1
&#215; 10<sup>6</sup> B16-F10 cells per mouse, subcutaneously into
the right flank, to induce the tumor.<xref rid="ref63" ref-type="bibr"/> The tumors were allowed to grow for 10 days (to 50&#8211;100 mm<sup>3</sup>) before treatment.</p></sec><sec id="sec2.3.3"><label>2.3.3</label><title>Treatment Groups</title><p>On the 10th day
after B16&#8211;F10 cell inoculation, when the tumor volume reached
&#8764;100 mm<sup>3</sup>, the mice were randomly assigned into seven
groups (<italic toggle="yes">n</italic> = 5 mice/group). Group 1 was the control
(naive group) containing tumor-free animals. The animals in groups
2&#8211;7 had melanoma tumors and received the following intratumoral
(IT) treatments: group 2 = 60 &#956;L saline solution (negative control);
group 3 = dacarbazine (positive control); group 4 = free BVC; group
5 = NLCs prepared with LO (NLC-L); group 6 = NLCs prepared with LO
plus BVC<sub>S75</sub> (NLC-L-BVC); and group 7 = LO-free NLCs plus
BVC<sub>S75</sub> (NLC-BVC).</p></sec><sec id="sec2.3.4"><label>2.3.4</label><title>Pharmacokinetic Study (Local Microdialysis
Inside the Tumor)</title><p>The pharmacokinetic evaluation of BVC<sub>S75</sub> (free and encapsulated) in the melanoma model was performed
by tissue microdialysis<named-content content-type="bibref-group">
<xref rid="ref64" ref-type="bibr"/>&#8722;<xref rid="ref65" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref66" ref-type="bibr"/>
</named-content> using CMA 20 probes (4 mm, CMA
Microdialysis, Kista, Switzerland). Microdialysis was carried out
on the animals between the 10th and 14th days after melanoma induction.
Previously, the probes were calibrated <italic toggle="yes">in vitro</italic> to
ensure that their relative recovery of BVC<sub>S75</sub> by gain (dialysis)
and by loss (retrodialysis) were similar.<xref rid="ref67" ref-type="bibr"/> A BVC<sub>S75</sub> concentration of 5 &#956;g/mL in perfusion
fluid consisting of 0.05 M phosphate buffer at pH 7.4 was used for
probe calibration. A 1.5 &#956;L/min flow rate was maintained using
a PHD22/2000 infuser (Harvard Apparatus, MA, USA) with 1 mL syringes.
A previously described HPLC bioanalytical study was employed for BVC<sub>S75</sub> quantification in the microdialysate samples.<xref rid="ref31" ref-type="bibr"/> The samples were injected directly into the
HPLC system without further processing.</p><p>The procedure was carried
out as shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>. After the tumor
reached a volume between 200&#8211;400 mm<sup>3</sup>, mice from
the free BVC, NLC-L-BVC, and NLC-BVC treatment groups (<italic toggle="yes">n</italic> = 5 per group) were anesthetized with urethane (1,000 mg/kg) prior
to sample collection. After anesthesia, the probes were inserted tangentially
into the upper third portion of the tumor and left in place for 1
h to stabilize. Formulations containing 5 mg/mL BVC<sub>S75</sub>,
in solution or encapsulated, were injected into the center of the
tumor. The dialyzate was collected for unbound BVC<sub>S75</sub> quantification
by HPLC after 3 min and then at 30 min intervals. In two animals from
each group, after the experiment, the buffer solution was replaced
with 0.5% BVC<sub>S75</sub>, and the probe was stabilized for 1 h
for subsequent collection of 3 &#215; 30 min samples and calculation
of <italic toggle="yes">in vivo</italic> retrodialysis (<italic toggle="yes">recovery by loss</italic>). The other three animals from each group were euthanized, and their
tumors were dissected. The dissected tissue was subjected to acid
extraction<xref rid="ref68" ref-type="bibr"/> to determine the residual
concentration of BVC<sub>S75</sub> in the tumor.</p><p>PKanalix software
(version 2021, Lixoft<sup>&#169;</sup>) was employed
to calculate the following pharmacokinetic parameters from the in
situ BVC<sub>S75</sub> concentration&#8211;time data: elimination
rate constant (ke), tissue half-life (<italic toggle="yes">t</italic>
<sub>1/2</sub>), area under the unbound concentration&#8211;time curve (AUC),
and initial unbound tissue concentration (C<sub>0</sub>). Each parameter
was statistically evaluated by two-way ANOVA (&#945; = 0.05) followed
by Tukey&#8217;s test using GraphPad Prism software, version 8 (California,
USA).</p><p>NLC formulations were labeled with 0.01% rhodamine PE
for subsequent
fluorescence analysis of the tumor to confirm the permanence of the
nanoparticles within it. Histological slides of the tumor tissue from
euthanized animals were analyzed under an inverted microscope equipped
with epi-fluorescence lighting and a digital camera (Leica DMI6000)
for image capture.</p></sec><sec id="sec2.3.5"><label>2.3.5</label><title>Antitumor Activity in Melanoma-Induced Mice</title><p>After tumor growth (<xref rid="sec2.3.2" ref-type="sec">Section <xref rid="sec2.3.2" ref-type="sec"/>
</xref>), four sessions of each treatment were carried out
(as described in <xref rid="sec2.3.3" ref-type="sec">Section <xref rid="sec2.3.3" ref-type="sec"/>
</xref>), with a two-day interval between sessions. The animals
were also observed daily for possible signs of adverse reactions (lethargy,
inability to walk, weight loss). The animals&#8217; body mass and
feed were quantified weekly using an analytical balance (AND HM-202,
EUA) with a digital scale. Every 2 days throughout the study, the
dimensions (length and width, in mm) of the tumors were measured with
a PD 200 (Vonder, Jundia&#237;, SP, Brazil) digital caliper (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A). Tumor volumes
(mm<sup>3</sup>) were calculated according to <xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula"/>
</xref>
<xref rid="ref69" ref-type="bibr"/> Seven days after
the end of the treatments, the animals were euthanized with ketamine
(300 mg/kg) and xylazine (30 mg/kg) intraperitoneally.</p><p>The chemotherapy
agent dacarbazine is a reference drug for the treatment of metastatic
melanoma.<named-content content-type="bibref-group">
<xref rid="ref70" ref-type="bibr"/>,<xref rid="ref71" ref-type="bibr"/>
</named-content> It was used in this study as a positive
control at a dosage of 80 mg/kg.<xref rid="ref72" ref-type="bibr"/> As for
BVC<sub>S75</sub>, we used a concentration (8 mg/kg) that took into
consideration the anesthetic&#8217;s clinical doses.<xref rid="ref73" ref-type="bibr"/> In the animals treated with the control formulation, i.e.,
NLC without bupivacaine (NLC-L), the injected formulations had the
same particle concentration (3.1 &#215; 10<sup>13</sup> particles/mL)
as those of the NLCs containing BVC<sub>S75</sub> (NLC-L-BVC and NLC-BVC).<disp-formula id="eq1"><label>1</label><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="mp5c00254_m001.jpg"/><mml:math id="d1e836" display="block"><mml:mrow><mml:mi>Tumor volume</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>tumor length</mml:mi><mml:mo>&#215;</mml:mo><mml:mi>tumor widt</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></disp-formula>
</p></sec><sec id="sec2.3.6"><label>2.3.6</label><title>Toxicological Analysis</title><sec id="sec2.3.6.1"><label>2.3.6.1</label><title>Biochemical Analytes in Serum</title><p>Immediately after euthanasia, blood samples were taken via cardiac
puncture of the animals in each treatment group (as described in <xref rid="sec2.3.3" ref-type="sec">Section <xref rid="sec2.3.3" ref-type="sec"/>
</xref>) for the
measurement of biochemical analytes in serum: alanine aminotransferase
(ALT, IU/L), aspartate aminotransferase (AST, IU/L), creatine kinase-MB
isoform (CK-MB, IU/L), and urea (mg/dL). ALT, AST, CK-MB, and urea
were analyzed using the kinetic method. All measurements were carried
out using the automated AU5800 Series Clinical Chemistry Analyzer
(Beckman Coulter).</p></sec><sec id="sec2.3.6.2"><label>2.3.6.2</label><title>Histopathological Analysis</title><p>After
euthanasia and blood collection, the mice were placed on a surgical
field, and, using a scalpel, a straight frontal incision was made
for the excision of the spleen, liver, lungs, kidneys, and tumor/skin.
The collected organs and the tumor were then placed in containers
with 10% formaldehyde solution and phosphate buffer (pH 7.4). Morphological
analyses were carried out according to the standard protocol established
in the literature.<xref rid="ref74" ref-type="bibr"/> The slices were stained
with hematoxylin/eosin (HE), analyzed/photographed using a Leica optical
microscope (Leica Microsystems, Switzerland) at 5 &#215; and 10 &#215;
magnifications, and processed with Leica 4.2.0 software (Leica Microsystems,
Switzerland).</p><p>Clark&#8217;s classification was used to assess
the degree of tumor invasion in the animal&#8217;s epidermis as follows:
I) the cancer is restricted to the epidermis, II) there is invasion
of the papillary dermis, III) the tumor fills the entire papillary
dermis without invading the reticular dermis, IV) there is invasion
of the reticular dermis, and V) there is invasion of the hypodermis.<named-content content-type="bibref-group">
<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref75" ref-type="bibr"/>,<xref rid="ref76" ref-type="bibr"/>
</named-content> The prognosis for melanoma therapy
is related to the depth and thickness of tumor cell invasion into
the epidermis.<named-content content-type="bibref-group">
<xref rid="ref76" ref-type="bibr"/>,<xref rid="ref77" ref-type="bibr"/>
</named-content> The histological criteria considered
to be a response to the tested treatments were mainly necrosis,<xref rid="ref78" ref-type="bibr"/> reduction in the size of the neoplastic region,<xref rid="ref79" ref-type="bibr"/> the presence of inflammatory infiltrate,<named-content content-type="bibref-group">
<xref rid="ref80" ref-type="bibr"/>,<xref rid="ref81" ref-type="bibr"/>
</named-content> and stromal fibroplasia.<named-content content-type="bibref-group">
<xref rid="ref82" ref-type="bibr"/>,<xref rid="ref83" ref-type="bibr"/>
</named-content>
</p></sec><sec id="sec2.3.6.3"><label>2.3.6.3</label><title>NMR-Metabolomics</title><p>To access the
metabolic profile of the animals&#8217; livers, after euthanasia,
the tissue was dissected, frozen in liquid nitrogen, and conserved
at &#8722;80 &#176;C. Tissue homogenization and metabolite extraction
were carried out in 50 mg samples of frozen liver tissues resuspended
in 1 mL of cold phosphate buffer (100 mM, pH 7.4) and agitated in
a Potter&#8211;Elvehjem homogenizer. Subsequently, 1 mL of the homogenate
was mixed with methanol:chloroform:water (1:1:0.8, v/v) for metabolite
extraction. Finally, the samples were centrifugated at 1000&#215;
g for 10 min, and the aqueous phase was collected, dried in a vacuum
concentrator, and conserved at &#8722;80 &#176;C until NMR analysis.
For that, the dry samples were resuspended in 600 &#956;L of D<sub>2</sub>O-phosphate buffer (0.1 M, pH 7.4) and 0.5 mM of trimethylsilylpropionate
(TMSP-d4 signal). The samples were transferred to 5 mm NMR tubes for
spectra acquisition in a Varian Inova spectrometer (Agilent Technologies
Inc., Santa Clara, CA, USA) equipped with a triple-resonance cold
probe and operating at a 1H resonance frequency of 600 MHz.<xref rid="ref1" ref-type="bibr"/> H NMR spectra acquisition was performed with
256 scans collected with 32 K data points over a spectral width of
8,000 Hz. 2D NMR <sup>1</sup>H&#8211;<sup>1</sup>H-TOCSY spectra
were acquired using a spectral width of 8,000 Hz and 128 increments
with 56 transients of 2k complex points for each free induction decay.
2D NMR <sup>1</sup>H&#8211;<sup>13</sup>C-HSQC spectra were recorded
with a spectral width of 8,000 Hz &#215; 25,133 Hz and 128 increments
with 60 transients of 2k complex points. In both 2D NMR spectra and
1H-NMR spectra, a 1.5-s relaxation delay was incorporated between
scans with a continual water presaturation radiofrequency (RF) field
to eliminate the residual water signal. Spectra were converted and
processed with TopSpin 4.0.3 (Bruker BioSpin, Rheinstetten, Germany),
cosine multiplication (ssb 2), zero-filling to 64 k data points, manual
phasing, baseline correction, and calibration to TSP-d4/TMS signals
(&#948; 0 ppm). The signal assignment was based on matching 1D spectral
information to reference spectra available in Chenomx 9.0 (Edmonton,
AB, Canada) and the human metabolic database (HMDB) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.hmdb.ca">www.hmdb.ca</uri>). In instances where confirmation
was required, the 2D 1H-1H-TOCSY/<sup>1</sup>H&#8211;<sup>13</sup>C-HSQC spectra were employed to validate the identity of specific
metabolites.</p><p>Spectral integration and total area normalization
of selected signals were carried out in Amix-Viewer 3.9.15 (Bruker
Biospin, Rheinstetten, Germany) to provide a quantitative measurement
of metabolic variations. Afterward, the metabolome data were analyzed
using MetaboAnalyst 6.0 (https://metaboanalyst.ca/), in which data
was normalized by median, and autoscaling was used. After, multivariate
analysis (principal component analysis (PCA) and sparse partial least-squares
discriminant analysis (sPLS-DA)) was employed along with univariate
analysis (a heatmap was constructed with significant metabolites calculated
by ANOVA (<italic toggle="yes">p</italic> &lt; 0.05), using the Pearson distance
measure and Ward&#8217;s clustering algorithm).</p></sec></sec><sec id="sec2.3.7"><label>2.3.7</label><title>Animal Survival</title><p>The survival probability
of the animals in each treatment group (as described in <xref rid="sec2.3.3" ref-type="sec">Section <xref rid="sec2.3.3" ref-type="sec"/>
</xref>) was calculated
by the Kaplan&#8211;Meier method.<xref rid="ref84" ref-type="bibr"/> The
nonparametric log-rank test was used to compare the curves between
the groups. Statistical data was generated with GraphPad Prism version
8.0.1 (GraphPad Software Inc., La Jolla, California, USA); <italic toggle="yes">p</italic> &lt; 0.05 was considered significant. Humanitarian intervention
was carried out when the tumor exceeds 10 mm diameter or in cases
of tumor ulceration, a 20% loss of the animal&#8217;s body mass,
loss of appetite, changes in mobility, and physiological behavior.
The approval certificates for the experimental protocols (#5736-1/2021
and #5940-1/2022) are provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Section 5 of the Supporting Information</ext-link>.</p></sec></sec><sec id="sec2.4"><label>2.4</label><title>Statistical Analysis</title><p>The results
were presented as mean &#177; standard deviation (SD). Statistical
analyses were conducted using GraphPad Prism, version 8.0.1. When
comparing multiple groups, a two-way analysis of variance (ANOVA)
was performed to assess whether there were significant differences
among the tests conducted, followed by Tukey&#8217;s posthoc test,
with <italic toggle="yes">p</italic> &lt; 0.05 considered significant.</p></sec></sec><sec id="sec3"><label>3</label><title>Results and Discussion</title><sec id="sec3.1"><label>3.1</label><title>Physicochemical Characterization of the Prepared
NLC Formulations</title><p>The formulations in this study were developed
and optimized by experimental design (DoE) and characterized by various
techniques&#58872;DLS, NTA, DSC, XRD, and TEM&#58872;regarding their
BVC<sub>S75</sub>
<italic toggle="yes">in vitro</italic> release kinetics and cytotoxicity.<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref85" ref-type="bibr"/>
</named-content> As described in the Methods section (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), an NLC formulation containing a synthetic
liquid lipid but no lavender oil (NLC-BVC) was used for comparison
with NLC-L-BVC to investigate whether lavender oil could enhance bupivacaine&#8217;s
effect in melanoma treatment. Natural lipids, such as lavender oil,
are highly biocompatible and easily metabolized, reducing the risk
of long-term accumulation and adverse reactions. However, their variable
composition may affect formulation consistency and reproducibility.<xref rid="ref86" ref-type="bibr"/> Conversely, synthetic lipids provide a consistent
chemical composition, greater stability, and lower cost but may be
toxic and are not biodegradable, potentially leading to accumulation
in the body.<xref rid="ref87" ref-type="bibr"/>
<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> summarizes the physicochemical properties
of both NLC formulations, providing insights into their potential
advantages and limitations for therapeutic use.</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Physicochemical characterization&#58872;Size,
Polydispersity Index (PDI), Zeta Potential (ZP), Nanoparticle Concentration
(NC), and BVC<sub>S75</sub> Encapsulation Efficiency (%ee)&#58872;of
the Formulations with Bupivacaine (NLC-L-BVC and NLC-BVC) and with
Lavender Oil Alone (NLC-L)</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">Formulation</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">Size
(nm)</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">PDI</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">ZP (mV)</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">NC (x&#160;10<sup>13</sup>/mL)</th><th align="center" colspan="1" rowspan="1">%EE</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>NLC-L</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">195.4&#160;&#177;&#160;1.8</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.138&#160;&#177;&#160;0.03</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">-26.8&#160;&#177;&#160;0.8</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">3.1&#160;&#177;&#160;0.2</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>NLC-L-BVC</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">200.5&#160;&#177;&#160;2.4</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.140&#160;&#177;&#160;0.02</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">-34.0&#160;&#177;&#160;0.6</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">3.8&#160;&#177;&#160;0.3</td><td align="left" colspan="1" rowspan="1">89.0&#160;&#177;&#160;2.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>NLC-BVC</bold>
<xref rid="tbl2fn1" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">165.9&#160;&#177;&#160;1.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.123&#160;&#177;&#160;0.05</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">-37.0&#160;&#177;&#160;1.1</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">8.8&#160;&#177;&#160;0.1</td><td align="left" colspan="1" rowspan="1">91.0&#160;&#177;&#160;3.4</td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>a</label><p>See ref <xref rid="ref85" ref-type="bibr" specific-use="ref-style=base-text"/>.</p></fn></table-wrap-foot></table-wrap><p>The data in <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> reveal nanoparticles of ideal size, PDI, ZP (homogeneous
and not
prone to fusion), and concentration for infiltrative application in
tumor tissue.<named-content content-type="bibref-group">
<xref rid="ref88" ref-type="bibr"/>&#8722;<xref rid="ref89" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref90" ref-type="bibr"/>
</named-content> Both of the BVC<sub>S75</sub>-containing formulations
exhibited high encapsulation efficiency.</p></sec><sec id="sec3.2"><label>3.2</label><title>Pharmacokinetic Study (Local Microdialysis
in the Tumor)</title><p>Surgery on primary tumors associated with anesthesia
has been an essential part of cancer therapy.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref91" ref-type="bibr"/>
</named-content> In order to assess the pharmacokinetic parameters
of BVC<sub>S75</sub> (free and NLC-encapsulated) in melanoma tumors,
we used the local microdialysis (directly in the tumor) technique,
which allows the unbound drug concentration to be harvested over time
from the tumor&#8217;s interstitial space fluid through the probe&#8217;s
semipermeable membrane, perfused with an isosmotic solution.<named-content content-type="bibref-group">
<xref rid="ref67" ref-type="bibr"/>,<xref rid="ref92" ref-type="bibr"/>
</named-content>
</p><p>The <italic toggle="yes">in vitro</italic> calibration of the microdialysis
probes resulted in BVC<sub>S75</sub> relative recovery of 22.0 &#177;
1.0% by gain (dialysis), similar to the recovery of 23.0 &#177; 0.8%
by loss (retrodialysis), indicating that the drug does not bond to
the microdialysis system tubing and confirming that retrodialysis
can be used to calibrate the probes <italic toggle="yes">in vivo</italic>. The
BVC<sub>S75</sub> average <italic toggle="yes">in vivo</italic> relative recovery
was 14.7 &#177; 0.9%. This average value was used to back-calculate
the real unbound BVC<sub>S75</sub> concentrations inside the tumor.</p><p>BVC<sub>S75</sub> concentration inside the tumor tissue was plotted
as a function of sample collection time, as shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Local unbound concentration
inside the tumor as a function of time.
Data represent mean &#177; SD (<italic toggle="yes">n</italic> = 5). Free BVC =
unbound solution of 0.5% bupivacaine S75:R25; NLC-L-BVC = nanostructured
lipid carrier with lavender oil and 0.5% of BVC<sub>S75</sub>; NLC-BVC
nanostructured lipid carrier with 0.5% of BVC<sub>S75</sub>; and no
lavender oil.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="mp5c00254_0001.jpg"/></fig><p>As expected, the unbound concentrations of BVC<sub>S75</sub> inside
the tumor decreased with time, but the decrease was significantly
faster in the animals treated with free BVC<sub>S75</sub> than in
the groups treated with encapsulated BVC<sub>S75</sub>. Therefore,
nanoencapsulation in NLC-L-BVC or NLC-BVC promoted a sustained release
of BVC<sub>S75</sub>, in agreement with previous results from <italic toggle="yes">in vitro</italic> release kinetics,<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref85" ref-type="bibr"/>
</named-content> increasing
the LA concentration in the tumor tissue.</p><p>The pharmacokinetic
parameters determined from the unbound BVC<sub>S75</sub> concentration
inside the tumor (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>) show how drug encapsulation into the nanoparticles
affected the anesthetic&#8217;s pharmacokinetics.</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>3</label><caption><title>Pharmacokinetic Parameters Calculated
from the BVC<sub>S75</sub> Unbound Concentration&#8211;Time Profiles
inside the Tumor Tissue</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">Parameters</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">free BVC</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">NLC-L-BVC</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">NLC-BVC</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ke (h<sup>&#8211;1</sup>)</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.91&#160;&#177;&#160;0.19</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.16&#160;&#177;&#160;0.08<xref rid="tbl3fn1" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.18&#160;&#177;&#160;0.10<xref rid="tbl3fn1" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.80&#160;&#177;&#160;0.17</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">5.8&#160;&#177;&#160;3.60<xref rid="tbl3fn2" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">4.9&#160;&#177;&#160;2.70<xref rid="tbl3fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8209;&#8734;</sub> (&#956;g&#183;h/mL)</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">178&#160;&#177;&#160;96</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2005&#160;&#177;&#160;712<xref rid="tbl3fn1" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1243&#160;&#177;&#160;230<xref rid="tbl3fn3" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>0</sub> (&#956;g/mL)</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">509.1&#160;&#177;&#160;315.2</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">464.8&#160;&#177;&#160;127.7</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">463.3&#160;&#177;&#160;159.1</td></tr></tbody></table><table-wrap-foot><fn id="tbl3fn1"><label>a</label><p>
<italic toggle="yes">p</italic> &lt; 0.0001
in comparison to free BVC<sub>S75</sub>.</p></fn><fn id="tbl3fn2"><label>b</label><p>
<italic toggle="yes">p</italic> &lt; 0.05.</p></fn><fn id="tbl3fn3"><label>c</label><p>
<italic toggle="yes">p</italic> &lt; 0.01.</p></fn></table-wrap-foot></table-wrap><p>The release profile of BVC<sub>S75</sub> encapsulated
in NLC was
like that determined by previous <italic toggle="yes">in vitro</italic> release
assays.<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref85" ref-type="bibr"/>
</named-content> The unencapsulated drug fraction led to
rapid release (&#8220;<italic toggle="yes">burst effect</italic>&#8221;) observed
as a high concentration at time zero (C<sub>0</sub>). BVC<sub>S75</sub> fractions encapsulated in NLCs&#8217; lipid cores also caused high
initial concentrations but then promoted a sustained release observed
until the end of the experiment.</p><p>Although it cannot be visualized
in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref> due to
the log scale (Y-axis), high variability
was observed for the nanoformulations&#8217; concentration&#8211;time
profiles. Therefore, no statistically significant (<italic toggle="yes">p</italic> &lt; 0.05) differences were detected between the nanoformulations&#8217;
pharmacokinetic metrics. A comparison between the nanoformulations
and the free drug showed that free BVC<sub>S75</sub>&#8217;s elimination
rate constant in the tumor tissue, 0.91 &#177; 0.19 h<sup>&#8211;1</sup>, was around 5- to 6-fold faster than that estimated for the NLC-L-BVC
and NLC-BVC formulations (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>). The half-life time increased from &#8764;1 h (free
BVC) to 5&#8211;6 h when the drug was encapsulated in either type
of NLC, with a significant difference (<italic toggle="yes">p</italic> &lt; 0.05)
between the free BVC and NLC-L-BVC groups. Accordingly, the AUC was
higher in the groups treated with NLC-L-BVC (2005 &#177; 712 &#956;g&#183;h/mL, <italic toggle="yes">p</italic> &lt; 0.001) and NLC-BVC (914 &#177; 204 &#956;g&#183;h/mL, <italic toggle="yes">p</italic> &lt; 0.05) than those treated with free BVC (178 &#177;
96 &#956;g&#183;h/mL), proving that the nanoformulations promote
increased exposure of the tumor to the anesthetic.</p><p>At the end
of the experiment (after 6 h of collection), the animals
were euthanized, and the BVC<sub>S75</sub> concentration in the tumors
was quantified by HPLC. BVC<sub>S75</sub> concentrations were around
four times higher in the animals treated with the nanoformulations
than in those treated with the free drug (<italic toggle="yes">p</italic> &lt;
0.05), as shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A. Subsequently, the NLC formulations were labeled with rhodamine
and applied to the tumor to determine the presence of the nanoparticles
in the tumor tissue. The histological slides of the tumor tissue from
euthanized animals were analyzed under a fluorescence microscope. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B depicts the tumor
of an animal treated with free BVC, which has no red fluorescence.
The presence of rhodamine in the tumor tissue (shown by the red color
in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>C,D) is
an indication that nanoparticles are still in the tumor after the
experiment and that the concentration of BVC<sub>S75</sub> is higher
in tumors treated with NLC formulations, revealing that the NLC prolongs
drug release at the site of action, protecting BVC<sub>S75</sub> from
normal clearance and favoring its interaction with tumor cells.<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref93" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>(A)
Residual posteuthanasia intratumoral BVC<sub>S75</sub> concentration
after 8 h. Fluorescence microscopy images of tumors treated with free
BVC (B), NLC-L-BVC (C), or NLC-BVC (D). The NLC formulations were
labeled with red fluorescent rhodamine-PE. Statistical analysis carried
out by unpaired Student&#8217;s t-test; * <italic toggle="yes">p</italic> &lt;
0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="mp5c00254_0002.jpg"/></fig></sec><sec id="sec3.3"><label>3.3</label><title>In Vivo Antitumor Activity in Melanoma-Induced
Mice</title><sec id="sec3.3.1"><label>3.3.1</label><title>Effect of Treatments on the Primary Tumor</title><p>The intradermal implant of B16&#8211;F10 tumor cells in C57BL/6J
mice is a common studies model, as it produces aggressively growing
tumors with invasive and metastatic profiles, given the tumor&#8217;s
vertiginous evolution.<xref rid="ref58" ref-type="bibr"/> In this tumor
induction model, six different treatments (see <xref rid="sec2.3.3" ref-type="sec">section <xref rid="sec2.3.3" ref-type="sec"/>
</xref>) were administered intratumorally
to determine their effect on the primary tumor. The evolution of the
primary tumors and their histopathological features were analyzed
both during treatment and post-treatment.</p><sec id="sec3.3.1.1"><label>3.3.1.1</label><title>Evolution of Primary Tumor During Treatment</title><p>The efficacy of the treatments on the primary tumor was evaluated
considering the tumor volume (TV) during the four treatment sessions
(16 days) and in the post-treatment as shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B. The group of animals treated with saline (negative control)
showed rapid and exponential tumor growth. At day 16, treatment with
dacarbazine (positive control) inhibited tumor volume by 30% compared
to the negative control (<italic toggle="yes">p</italic> &lt; 0.05). A small reduction
of tumor volume (17%) was registered in the animals treated with free
BVC, while treatments with NLC-L-BVC and NLC-BVC resulted in substantial
TV reduction of 70% and 72%, respectively, compared to the negative
control (<italic toggle="yes">p</italic> &lt; 0.0001), as detailed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Figure S2B</ext-link>. The NLC formulation with lavender
oil alone (NLC-L) reduced the tumor growth by 67% in comparison to
the negative control (<italic toggle="yes">p</italic> &lt; 0.0001). These data
demonstrated that all NLC formulations tested reduced tumor growth.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>(A) Timeline
of the experimental design: T1, T2, T3, and T4 = treatments.
(B) Evolution of the primary tumor during and after treatment of animals
with negative control = 0.9% NaCl, positive control = dacarbazine,
free BVC (0.5%), lavender oil formulation (NLC-L), or the formulations
containing 0.5% BVCS75 (NLC-L-BVC and NLC-BVC).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="mp5c00254_0003.jpg"/></fig></sec><sec id="sec3.3.1.2"><label>3.3.1.2</label><title>Evolution of the Primary Tumor after Treatment</title><p>We analyzed the post-treatment effect on the growth of the animals&#8217;
primary tumors. <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A shows the respective tumor volumes of the animals in each treatment
group during the one-week period after the end of treatment (day 22). <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>B is a graphical
representation of the size of the tumors excised at the end of this
period.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Analysis of post-treatment tumor growth. (A) Comparison of tumor
volume at day 16 (last day of treatment) and 1 week after (day 22)
the end of treatment with negative control (0.9% NaCl), positive control
(dacarbazine), free BVC (0.5%), lavender oil formulation (NLC-L),
or formulations containing 0.5% BVC<sub>S75</sub>: NLC-L-BVC and NLC-BVC.
(B) Representative examples of tumors from each treatment, excised
at day 22 (same scale). Statistical analysis: one-way ANOVA plus posthoc
Tukey. * <italic toggle="yes">p</italic> &lt; 0.05; *** <italic toggle="yes">p</italic> &lt;
0.001; n.s. = nonsignificant. No statistical analysis was applied
to the negative control group because only one animal in this group
survived until day 22.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr4" position="float" orientation="portrait" xlink:href="mp5c00254_0004.jpg"/></fig><p>
<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A,B shows
that intensive tumor growth was observed in the negative control group
on day 22 (1638 mm<sup>3</sup> of growth). Tumor growth was significantly
reduced by treatments with NLC-L-BVC and NLC-BVC (257 mm<sup>3</sup> and 95 mm<sup>3</sup> of growth, respectively), which were more
effective than treatment with dacarbazine or free BVC (872 mm<sup>3</sup> [<italic toggle="yes">p</italic> &lt; 0.05] and 1112 mm<sup>3</sup> [<italic toggle="yes">p</italic> &lt; 0.001] of growth, respectively). Among the treatments,
formulations with BVC<sub>S75</sub> encapsulated in NLC resulted in
the least tumor growth, with no significant differences between the
treatment and post-treatment periods. Conversely, the antitumor effect
of the lavender oil nanoparticle (NLC-L) decreased in the post-treatment
period; the tumor volume increased to 878 mm<sup>3</sup>, a significant
difference from day 16 (<italic toggle="yes">p</italic> &lt; 0.001), similar to
what was observed with dacarbazine.</p><p>There was a significant
reduction in tumor growth in the animals
treated with NLC-L-BVC and NLC-BVC compared to the other treatments
during the treatment and post-treatment period. Considering the pharmacokinetic
findings, these results could be due to the prolonged release of BVC<sub>S75</sub> promoted by the nanoparticles that not only allowed the
anesthetic to remain in the tumor tissue for longer but also promoted
a greater concentration of the drug at the site of action, improving
the action of BVC<sub>S75</sub>. Moreover, as proposed by Nguyen et
al., NLCs could modulate the microenvironment of solid tumors, enhancing
drug efficacy and possibly blocking their cellular resistance mechanism,<named-content content-type="bibref-group">
<xref rid="ref90" ref-type="bibr"/>,<xref rid="ref94" ref-type="bibr"/>
</named-content> which may have contributed to the superior performance observed.</p></sec><sec id="sec3.3.1.3"><label>3.3.1.3</label><title>Histological Analysis of the Primary Tumor</title><p>Histopathological images of the animals&#8217; tumor groups are
shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>;
the complete histopathological analysis is described in Section 3
of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>). As expected, the animals in the naive
group had normal skin with well-defined layers. The animals in the
negative control group (untreated) showed an aggressive tumor profile
characterized by extensive areas of necrosis and invasion of the underlying
muscle and fat tissue, classified as Clark V (see &#8220;Methods&#8221;).
Tumors in animals treated with dacarbazine and free BVC displayed
a Clark IV level, as did the tumors of animals treated with NLC-L-BVC
and NLC-BVC. Those treated with the NLC-L formulation displayed a
Clark V level. Thus, the histopathological analysis showed that all
the treatments (except NLC-L) decreased the degree of tumor invasion;
BVC<sub>S75</sub> encapsulation did not bring about a better result
for this parameter. Additionally, tumors treated with the NLC-L formulation
presented an aggressive profile similar to untreated tumors, which
could result in a worse post-treatment prognosis.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Histopathological sections
of excised tumors (H&amp;E staining):
naive (A), negative control (B), dacarbazine (C), free BVC (D), NLC-L-BVC
(E), NLC-BVC (F), and NLC-L (G). Scale bar = 100 &#956;m, magnification:
5&#215; and 10&#215;. The black arrows point to areas of necrosis,
asterisks represent areas of edema, and circled areas show inflammatory
infiltrate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr5" position="float" orientation="portrait" xlink:href="mp5c00254_0005.jpg"/></fig><p>Despite the recognized antitumor properties of
lavender oil,<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>,<xref rid="ref95" ref-type="bibr"/>
</named-content> its <italic toggle="yes">in vivo</italic> efficacy
did not align with expectations
and contrasts with the <italic toggle="yes">in vitro</italic> results reported
in a previous study<xref rid="ref42" ref-type="bibr"/> since an aggressive
tumor profile was seen after NLC-L treatment (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>G). Moreover, the combination of LO and BVC<sub>S75</sub> in the same nanoparticle did not produce a synergistic
effect for the local treatment of melanoma. This is likely attributable
to the complexity of the tumor microenvironment and other pharmacological
aspects affecting the response to the oil and the combined therapy.
Unfortunately, it is not uncommon in cancer research for promising <italic toggle="yes">in vitro</italic> results to fail to translate into <italic toggle="yes">in vivo</italic> outcomes.<named-content content-type="bibref-group">
<xref rid="ref96" ref-type="bibr"/>,<xref rid="ref97" ref-type="bibr"/>
</named-content>
</p><p>In the next step, the systemic
effects of the treatments were evaluated.</p></sec></sec></sec><sec id="sec3.4"><label>3.4</label><title>Systemic Evaluation of the Treatments&#8217;
Effectiveness and Toxicological Profiles</title><p>Clinical, biochemical,
and histopathological parameters were assessed to evaluate the effectiveness
and toxicological profile of the treatments. Body weight and food
intake are key clinical parameters for assessing possible adverse
effects caused by a neoplasm, treatments, or both.<named-content content-type="bibref-group">
<xref rid="ref98" ref-type="bibr"/>,<xref rid="ref99" ref-type="bibr"/>
</named-content> The biochemical analytes ALT, AST, CK-MB, and urea were assessed
for possible treatment-related changes in the animals&#8217; metabolic
processes,<xref rid="ref100" ref-type="bibr"/> which also provided the NMR
metabolomic analysis of the liver.<xref rid="ref101" ref-type="bibr"/> Finally,
histopathological analyses of the organs were carried out to evaluate
the diagnostic perspective and the effects of the treatments on the
tissues.<xref rid="ref102" ref-type="bibr"/>
</p><sec id="sec3.4.1"><label>3.4.1</label><title>Weight and Ingestion of Food</title><p>The
weight and feed consumption of the animals were analyzed; the results
are shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>. There was a significant decrease in the weight of the animals in
the negative control (<italic toggle="yes">p</italic> &lt; 0.0001), dacarbazine,
and NLC-L (<italic toggle="yes">p</italic> &lt; 0.001) groups, in which the tumor
growth was greater than 870 mm<sup>3</sup>, compared to the naive
group (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A).
No significant decrease was observed in the body mass of the animals
treated with free BVC. Similar results were also seen in the animals
treated with both kinds of NLC containing BVC<sub>S75</sub> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A), reinforcing the
possible role of BVC<sub>S75</sub> in improving the prognosis in the
case of neoplasms.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Weight analysis and feed consumption during
the experiment. Average
weight (A) and feed consumption (B) by animals without treatment (naive)
and treatment with negative control (0.9% NaCl), positive control
(dacarbazine), free BVC (0.5%), lavender oil formulation (NLC-L),
or formulations containing 0.5% BVC<sub>S75</sub>: NLC-L-BVC and NLC-BVC.
Statistical analysis: two-way ANOVA plus posthoc Tukey. a = in comparison
to the naive group. *** <italic toggle="yes">p</italic> &lt; 0.001; **** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr6" position="float" orientation="portrait" xlink:href="mp5c00254_0006.jpg"/></fig><p>Average feed consumption (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>B) revealed no significant differences in
treated animals
in relation to the naive group during the experiment. A reduction
in feed consumption was only observed in the post-treatment period
in the negative control, dacarbazine, and NLC-L groups, which explains
the loss of body mass (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A) and lower survival rate (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B) observed in these animals.</p></sec><sec id="sec3.4.2"><label>3.4.2</label><title>Biochemical Profile</title><p>Biochemical
analyses of alanine transaminase (ALT), aspartate aminotransferase
(AST), creatine kinase MB (CK-MB), and urea were performed on the
serum of treated groups of animals (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>). ALT and AST are the most used markers
for the clinical diagnosis of liver damage,<named-content content-type="bibref-group">
<xref rid="ref103" ref-type="bibr"/>,<xref rid="ref104" ref-type="bibr"/>
</named-content> while elevations in serum urea levels can indicate renal overload
or nephrotoxicity.<named-content content-type="bibref-group">
<xref rid="ref105" ref-type="bibr"/>&#8722;<xref rid="ref106" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref107" ref-type="bibr"/>
</named-content> CK-MB is a key biomarker in diagnosing cardiac
damage, and as recently reported, it can be altered in colorectal,
lung, and hepatocellular cancers.<named-content content-type="bibref-group">
<xref rid="ref108" ref-type="bibr"/>,<xref rid="ref109" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Biochemical
parameters: serum ALT, AST, CK-MB activity, and urea
levels in the post-treatment period of animals treated with 0.9% NaCl,
dacarbazine, free BVC, NLC-L, NLC-L-BVC, or NLC-BVC. ALT (A), AST
(B), CK-MB (C), and urea (D). Statistical analysis: one-way ANOVA
plus posthoc Tukey. *<italic toggle="yes">p</italic> &lt; 0.05; **<italic toggle="yes">p</italic> &lt; 0.01; ***<italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr7" position="float" orientation="portrait" xlink:href="mp5c00254_0007.jpg"/></fig><p>Among the markers of liver damage, no significant
changes were
observed at the tumor level (untreated group) compared to the healthy
group. In terms of treatment toxicity, there was an increase in AST
levels only in the NLC-L treatment group (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>B), which may indicate a liver response to
the metabolization of LO.</p><p>Regarding the CK-MB levels (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>C), it was observed
that free BVC, dacarbazine, and
NLC-L treatments promoted changes in relation to the naive group (<italic toggle="yes">p</italic> &lt; 0.05). Concerning the animals treated with dacarbazine,
the increase in CK-MB corroborates reports in the literature on the
cardiotoxicity of this antineoplastic drug.<named-content content-type="bibref-group">
<xref rid="ref110" ref-type="bibr"/>,<xref rid="ref111" ref-type="bibr"/>
</named-content> The increase in CK-MB levels induced by free BVC was not observed
in the groups treated with encapsulated BVC<sub>S75</sub> (NLC-L-BVC
and NLC-BVC), for which CK-MB levels were comparable to those of the
naive group. This indicates that encapsulation reduces the cardiotoxicity
of free BVC.</p><p>As for serum urea levels (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>D), the primary tumor increased the concentration
of
this metabolite. Among the treatments, only free BVC increased urea
levels compared to the naive group (<italic toggle="yes">p</italic> &lt; 0.05).
This increase was not observed in the groups treated with encapsulated
BVC<sub>S75</sub>, revealing that the prolonged drug release promoted
by the nanoparticles (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) promotes greater effectiveness in treating the primary tumor
at a systemic level.</p><p>Finally, the tissue-to-body weight coefficients
(for the liver,
heart, lungs, kidney, and spleen), which relate the weight of specific
tissues to the total body weight of the animal, were calculated as
the ratio of the tissue&#8217;s wet weight (mg) to body weight (g)
in order to assess potential anatomopathological changes and toxicity<xref rid="ref112" ref-type="bibr"/> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>). The
data indicated that the heart, lungs, and kidneys of animals with
tumors showed no significant changes compared to the naive group.
However, in the liver, tumor induction led to an increase in its weight
relative to the animal&#8217;s body weight (tissue hypertrophy),
which was mitigated by the treatments, except for dacarbazine, corroborating
the direct effectiveness observed in the primary tumor. There was
an increase in the weight of the spleens of all tumor-induced animals,
which treatments with an NLC containing bupivacaine did not significantly
impact.</p></sec><sec id="sec3.4.3"><label>3.4.3</label><title>NMR Metabolomics of the Liver</title><p>NMR
metabolomic analysis is a technique used in cancer and drug toxicology
studies to identify the changes caused by these agents in normal and
tumor tissues.<xref rid="ref101" ref-type="bibr"/> The liver was chosen
for analysis because it is a common site of metastasis in this work&#8217;s
model<xref rid="ref113" ref-type="bibr"/> and due to its importance in various
biochemical processes besides the metabolization of xenobiotics.<named-content content-type="bibref-group">
<xref rid="ref114" ref-type="bibr"/>,<xref rid="ref115" ref-type="bibr"/>
</named-content> Two aspects were considered: first, whether the tumor induced metabolic
changes in the liver (and how treatments influenced these changes)
and, second, whether treatments themselves caused metabolic disturbances
that could indicate toxic effects.</p><p>The hydrophilic extracts
from the liver samples were analyzed using <sup>1</sup>H NMR spectroscopy,
which allowed for the identification of 34 distinct metabolites, as
illustrated in the reference spectrum provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>. Subsequently, both multivariate and univariate
analyses were performed on the liver metabolomic data, and the detailed
results of these analyses are presented in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>. PCA analysis (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>A) revealed a clear separation between the
naive and negative control (nontreated) groups, indicating cancer-induced
metabolic alterations in this tissue. When analyzing the sPLDA loadings
(<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>B), which
show the main metabolites responsible for separating the groups, the
metabolite hypoxanthine was shown to be the most important variable
(&gt;0.4) and was increased in the negative control group (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>C). It has been reported
in
the literature that an increase in hypoxanthine is commonly found
in tumor cells; consequently, it is considered a tumor biomarker.<xref rid="ref116" ref-type="bibr"/> Regarding the treatments, the NLC-L, NLC-L-BVC,
and NLC-BVC nanoformulations promoted a decrease in hypoxanthine (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>D), indicating their
effectiveness. These data agree with the observed reduction in tumor
growth (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>B).</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Results
of metabolic profiling of the liver. Multivariate analysis
(left): (A) principal component analysis (PCA) and (B) sparse partial
least-squares discriminant analysis (sPLS-DA). Univariate analysis
(right): (C) heatmap of significant metabolites (ANOVA, <italic toggle="yes">p</italic> &lt; 0.05) and (D) violin plot for the metabolite hypoxanthine.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr8" position="float" orientation="portrait" xlink:href="mp5c00254_0008.jpg"/></fig><p>On the other hand, there was a clear separation
in the PCA results
involving groups of treatments that contained LO. The heatmap in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>C reveals that the
amino acids tyrosine, phenylalanine, methionine, and leucine are increased
in relation to the naive and negative control groups. Additionally,
the metabolites choline, glutathione, UDP-glucose, AMP, GTP, lactate,
niacinamide, glucose, and taurine were diminished. This could indicate
the liver&#8217;s response to the metabolization of LO, as also observed
in the biochemical profile, with an increase in the serum concentrations
of AST (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>B).
Even though there are no reports in the literature on the toxicity
of this essential oil to the liver, these results indicate the requirement
of further studies to understand the cause of these alterations and
to determine whether they are a toxic response to LO, even when encapsulated
in nanoparticles.</p></sec><sec id="sec3.4.4"><label>3.4.4</label><title>Histopathologic Analysis of Organs (Spleen,
Liver, Lungs, and Kidneys)</title><p>Histopathology analysis of the
organs is shown in Section 4 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">Figure S6</ext-link>). In summary,
the liver, kidneys, and spleen revealed normal histological characteristics
in all groups. The pulmonary evaluation revealed that the naive, negative
control, NLC-L, and NLC-BVC groups had normal histological features.
The free BVC, NLC-L-BVC, and dacarbazine groups showed foci of moderate
to severe inflammatory infiltrates. Thus, histology results do not
indicate any substantial changes in any group studied.</p></sec></sec><sec id="sec3.5"><label>3.5</label><title>Animal Survival</title><p>Animal survival was
determined as the time (in days) between tumor induction and the animal&#8217;s
death. In accordance with a previously established protocol,<xref rid="ref5" ref-type="bibr"/> animal euthanasia was performed in a controlled
and supervised manner to relieve pain whenever clinical signs of any
indication of pain or suffering (such as lethargy or severe weight
loss) were observed. <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>A compares the cumulative survival of the
animals in the experimental groups as a function of the length of
the experiment (22 days in total).</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>(A) Animal survival after melanoma induction.
The survival rate
was 100% in the naive, free BVC, and NLC-L-BVC groups; 80% in the
NLC-BVC group (1 animal died); 40% in the dacarbazine and NLC-L groups
(3 animals/group died); and 20% in the negative control group (4 animals/group
died). (B) Percentage of survival across treatments, indicating higher
survival odds for animals treated with BVC<sub>S75</sub> (free or
encapsulated).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr9" position="float" orientation="portrait" xlink:href="mp5c00254_0009.jpg"/></fig><p>The negative control group (untreated tumor) exhibited
the lowest
survival rate (20%). After treatment with dacarbazine and NLC-L, the
survival rate was 40%. Possible contributing factors to the observed
mortality in these groups include toxicity, as suggested by elevated
CK-MB levels (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>C) and metabolic alterations in the liver, as well as increased tumor
growth during the post-treatment period (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A). Regarding dacarbazine, the treatment&#8217;s
limited ability to extend overall survival may be attributed to chemoresistance.<xref rid="ref117" ref-type="bibr"/>
</p><p>The highest survival rates (100%, 100%,
and 80%) were observed
in the groups treated with bupivacaine (free BVC, NLC-L-BVC, and NLC-BVC,
respectively). Even though treatment with free BVC resulted in elevated
serum CK-MB levels (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>C) and no significant decrease in tumor growth (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig"/>
</xref> and <xref rid="fig4" ref-type="fig"/>), the animals in this group showed the highest survival rate, revealing
the beneficial effect of the anesthetic on the cancer&#8217;s prognosis,
in accordance with the literature.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref91" ref-type="bibr"/>,<xref rid="ref118" ref-type="bibr"/>
</named-content> The high survival
rate observed after encapsulation into the nanoparticles (NLC-L-BVC
and NLC-BVC, <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>B) confirms that it is promoted by the anesthetic.</p></sec><sec id="sec3.6"><label>3.6</label><title>Final Considerations</title><p>This study evaluated
the antitumor potential of two lipid nanoformulations prepared with
natural and synthetic excipients and containing bupivacaine on melanoma
tumor cells. The formulations consisted of BVC<sub>S75</sub> (0.5%)
encapsulated in NLC prepared with lavender essential oil (NLC-L-BVC)
or Capryol 90 (NLC-BVC) as the liquid lipid. The <italic toggle="yes">in situ</italic> pharmacokinetic analysis confirmed that the nanoparticles prolonged,
through sustained release, effective levels of BVC<sub>S75</sub> in
the tumor tissue, improving its pharmacological activity (inhibition
of tumor volume) compared to the free drug. Tumor volume was lower
in animals treated with NLC-L-BVC or NLC-BVC than in those treated
with the reference drug dacarbazine, and the formulations were effective
in inhibiting tumor growth during and after treatment. The systemic
parameters analyzed (animal weight, biochemical, and NMR metabolomics)
revealed no clinically relevant toxicity for the formulations and
confirmed that encapsulated BVC<sub>S75</sub> improved the prognosis
while showing no signs of systemic toxicity. Additionally, higher
survival rates in the immediate post-treatment period were observed
in all treatments with BVC.</p></sec></sec><sec id="sec4"><label>4</label><title>Conclusions</title><p>The obtained data evidenced
a better prognosis when BVC<sub>S75</sub> was used in the treatment
of melanoma, promoting higher survival
rates compared to the control groups (without BVC<sub>S75</sub>).
Encapsulation of BVC<sub>S75</sub> in NLC promoted its sustained release
at the site of action and, thus, greater antitumor effectiveness in
the local treatment of melanoma. Therefore, BVC-in-NLC can offer a
possible advancement in oncologic therapy with the benefit of greater
local action (anesthetic and antitumor effect) and improved prognostic
outcomes without systemic toxicity. Unfortunately, the association
of LO and BVC<sub>S75</sub> in lipid nanoparticles did not result
in a clear synergy for the local treatment of melanoma. Although NLC-L
(without BVC<sub>S75</sub>) displayed activity during the chemotherapy
treatment of the primary tumor, its post-treatment outcomes (tumor
volume, histopathological analysis, and systemic effects) were suboptimal.
In conclusion, natural (NLC-L-BVC) and synthetic (NLC-BVC) formulations
were found to be equally effective in the treatment of melanoma.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp5c00254_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>The authors thank Crist&#225;lia Prod. Quim. Farmac.
Ltd for the donation of BVC<sub>S75</sub> (Novabupi&#174;). This research
used the NMR facility of the Brazilian Bioscience National Laboratory
(LNBio), part of the Brazilian Center for Research in Energy and Materials
(CNPEM), a nonprofit organization under the supervision of the Brazilian
Ministry for Science, Technology, and Innovation (MCTI). The authors
would also like to thank the NMR facility staff of LNBio for their
support with the NMR data collecting and processing in Chenomx, especially
Dr. Maur&#237;cio L. Sforca and Dr. Silvana Rocco. The authors would
also like to express their gratitude to Dr. Valquiria Matheus for
her support in the analysis of the histopathological slides in this
study.</p></ack><notes id="notes1" notes-type="si"><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00254?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00254</ext-link>.<list list-type="simple" id="silist1"><list-item><p>Tumor microdialysis in an animal model (Figure S1);
additional information regarding tumor evolution during treatment
(Figure S2); histological analyses of the primary tumor in animals
of the naive group (Figure S3A), negative control group (Figure S3B),
and groups that received: dacarbazine (Figure S3C), free BVC (0.5%)
(Figure S3D), NLC-L-BVC (Figure S3E), NLC-BVC (Figure S3F) or NLC-L
(Figure S3G); tissue-to-body weight coefficients (for the liver, heart,
lungs, kidneys, and spleen) after treatment (Figure S4); representative <sup>1</sup>H NMR spectrum of the aqueous liver extract (Figure S5); histological
images of organs (spleen, liver, lungs, and kidneys) from animals
in the naive group and those treated with 0.9% NaCl, dacarbazine,
free BVC, NLC-L, NLC-L-BVC, or NLC-BVC, stained with H&amp;E (Figure
S6), certificates for the <italic toggle="yes">in vivo</italic> experimental protocols
(Figure S7) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00254/suppl_file/mp5c00254_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes2" notes-type="author-contributions"><p>Conceptualization,
G.G., E.P., and G.H.R.S; methodology, G.G. and G.H.R.S.; investigation,
G.G., G.H.R.S., L.D.M, F.V.C, T.C.M, L.B.O., B.V.A., L.L., and F.V.M;
formal analysis and data curation, G.G., G.H.R.S, T.DC., and E.P.;
writing&#58872;original draft preparation, G.G.; writing&#58872;review
and editing, G.G., G.H.R.S., L.D.M, T.D.C., and E.P.; visualization,
G.H.R.S., L.D.M., and T.D.C.; and supervision, project administration,
resources, and funding acquisition, T.D.C. and E.P. All authors have
read and agreed to the published version of the manuscript.</p></notes><notes id="notes3" notes-type="funding-statement"><p>This research
was funded by Funda&#231;&#227;o de Amparo &#224; Pesquisa do
Estado de S&#227;o Paulo (FAPESP grant #2019/17784&#8211;0 and
G.G. fellowship #2021/02575&#8211;7), Funda&#231;&#227;o de Amparo
&#224; Pesquisa do Estado do Rio Grande do Sul (FAPERGS # 19/2551-000278-6),
and Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico
(GG fellowship #130258/2021-0 and E.P. grant). The Article Processing
Charge for the publication of this research was funded by the Coordenacao
de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil (ROR
identifier: 00x0ma614).</p></notes><notes id="notes4" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><mixed-citation publication-type="book" id="cit1"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Yanagidate</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Strichartz</surname>, <given-names>G. R.</given-names></string-name></person-group><article-title>Local Anesthetics</article-title>. In <source>Handbook of Experimental
Phamacology</source>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Stein</surname>, <given-names>C.</given-names></string-name></person-group>, Eds.; <publisher-name>Springer</publisher-name>: <publisher-loc>Berlin Heidelberg</publisher-loc>, <year>2006</year>; Vol. <volume>177</volume>; pp. <fpage>95</fpage>&#8211;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-33823-9_4</pub-id>.<pub-id pub-id-type="pmid">17087121</pub-id></mixed-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Ji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><article-title>Safety and Efficacy
Concerns of Modern
Strategies of Local Anesthetics Delivery</article-title><source>3
Biotech.</source><year>2020</year><volume>10</volume><issue>8</issue><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1007/s13205-020-02309-y</pub-id><pub-id pub-id-type="pmcid">PMC7338310</pub-id><pub-id pub-id-type="pmid">32656066</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Bezu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><article-title>Local Anesthetics and
Immunotherapy:
A Novel Combination to Fight Cancer</article-title><source>Semin.
Immunopathol.</source><year>2023</year><volume>45</volume><issue>2</issue><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s00281-022-00960-6</pub-id><pub-id pub-id-type="pmid">36044068</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Boutros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Croce</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gili</surname><given-names>R.</given-names></name><name name-style="western"><surname>Massaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marconcini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arecco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tanda</surname><given-names>E. T.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>F.</given-names></name><article-title>The Treatment
of Advanced Melanoma: Current Approaches and New Challenges</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2024</year><volume>196</volume><fpage>104276</fpage><lpage>104290</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2024.104276</pub-id><pub-id pub-id-type="pmid">38295889</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>de
Moura</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>L. N. M.</given-names></name><name name-style="western"><surname>de Carvalho</surname><given-names>F. V.</given-names></name><name name-style="western"><surname>Rodrigues da Silva</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Lima Fernandes</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Brunetto</surname><given-names>S. Q.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Velloso</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><article-title>Docetaxel and Lidocaine Co-Loaded (NlC-in-Hydrogel)
Hybrid System Designed for the Treatment of Melanoma</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><issue>10</issue><fpage>1552</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13101552</pub-id><pub-id pub-id-type="pmid">34683846</pub-id><pub-id pub-id-type="pmcid">PMC8537790</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Wu
Chuang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bezu</surname><given-names>L.</given-names></name><article-title>Direct Cytotoxic
and Indirect, Immune-Mediated Effects of Local Anesthetics Against
Cancer</article-title><source>Front. Oncol.</source><year>2022</year><volume>11</volume><fpage>821785</fpage><lpage>821798</lpage><pub-id pub-id-type="doi">10.3389/fonc.2021.821785</pub-id><pub-id pub-id-type="pmid">35096626</pub-id><pub-id pub-id-type="pmcid">PMC8796204</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Ahn</surname><given-names>H. J.</given-names></name><article-title>Anesthesia
and Cancer Recurrence: A Narrative Review</article-title><source>Anesth.
Pain Med.</source><year>2024</year><volume>19</volume><fpage>94</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.17085/apm.24041</pub-id><pub-id pub-id-type="pmcid">PMC11089301</pub-id><pub-id pub-id-type="pmid">38725164</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Carnet
Le Provost</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bezu</surname><given-names>L.</given-names></name><article-title>Trial Watch:
Local Anesthetics in Cancer Therapy</article-title><source>Oncoimmunology</source><year>2024</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1080/2162402X.2024.2308940</pub-id><pub-id pub-id-type="pmcid">PMC10950281</pub-id><pub-id pub-id-type="pmid">38504848</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Tavare</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>N. J. S.</given-names></name><name name-style="western"><surname>Benzonana</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Takata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><article-title>Cancer Recurrence
after Surgery: Direct and Indirect Effects of Anesthetic Agents</article-title><source>Int. J. Cancer</source><year>2012</year><volume>130</volume><issue>6</issue><fpage>1237</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1002/ijc.26448</pub-id><pub-id pub-id-type="pmid">21935924</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dilger</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><article-title>Effects of
Local Anesthetics on Cancer
Cells</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>212</volume><fpage>107558</fpage><lpage>107570</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107558</pub-id><pub-id pub-id-type="pmid">32343985</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Chamaraux-Tran</surname><given-names>T.-N.</given-names></name><name name-style="western"><surname>Piegeler</surname><given-names>T.</given-names></name><article-title>The Amide Local Anesthetic
Lidocaine in Cancer Surgery&#58872;Potential
Antimetastatic Effects and Preservation of Immune Cell Function? A
Narrative Review</article-title><source>Front. Med.</source><year>2017</year><volume>4</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.3389/fmed.2017.00235</pub-id><pub-id pub-id-type="pmcid">PMC5742360</pub-id><pub-id pub-id-type="pmid">29326939</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><article-title>Local Anesthetic
Lidocaine and Cancer: Insight Into
Tumor Progression and Recurrence</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><fpage>669746</fpage><lpage>669758</lpage><pub-id pub-id-type="doi">10.3389/fonc.2021.669746</pub-id><pub-id pub-id-type="pmid">34249706</pub-id><pub-id pub-id-type="pmcid">PMC8264592</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Cata</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Perez-Gonzalez</surname><given-names>O.</given-names></name><article-title>Local Anesthetics:
Hunting for the
Holy Grail of Onco-Anesthesia</article-title><source>Pain Med.</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>219</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1093/pm/pnz327</pub-id><pub-id pub-id-type="pmid">31841154</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Grandhi</surname><given-names>R.
K.</given-names></name><name name-style="western"><surname>Perona</surname><given-names>B.</given-names></name><article-title>Mechanisms
of Action by Which Local Anesthetics Reduce
Cancer Recurrence: A Systematic Review</article-title><source>Pain
Med.</source><year>2019</year><volume>21</volume><issue>2</issue><fpage>401</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1093/pm/pnz139</pub-id><pub-id pub-id-type="pmid">31282958</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><article-title>Cytotoxicity of Amide-Linked Local
Anesthetics on Melanoma Cells via Inhibition of Ras and RhoA Signaling
Independent of Sodium Channel Blockade</article-title><source>BMC
Anesthesiol.</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1186/s12871-020-00957-4</pub-id><pub-id pub-id-type="pmid">32085741</pub-id><pub-id pub-id-type="pmcid">PMC7033929</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Schwartz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beitner</surname><given-names>R.</given-names></name><article-title>Detachment of the Glycolytic Enzymes,
Phosphofructokinase
and Aldolase, from Cytoskeleton of Melanoma Cells, Induced by Local
Anesthetics</article-title><source>Mol. Genet. Metab.</source><year>2000</year><volume>69</volume><issue>2</issue><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1006/mgme.2000.2960</pub-id><pub-id pub-id-type="pmid">10720443</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Karniel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beitner</surname><given-names>R.</given-names></name><article-title>Local Anesthetics Induce
a Decrease in the Levels of
Glucose 1,6- Bisphosphate, Fructose 1,6-Bisphosphate, and ATP, and
in the Viability of Melanoma Cells</article-title><source>Mol. Genet.
Metab.</source><year>2000</year><volume>69</volume><issue>1</issue><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1006/mgme.1999.2954</pub-id><pub-id pub-id-type="pmid">10655156</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Shah</surname><given-names>J.</given-names></name><name name-style="western"><surname>Votta-Velis</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Borgeat</surname><given-names>A.</given-names></name><article-title>New Local Anesthetics</article-title><source>Best Pract. Res., Clin. Anaesthesiol.</source><year>2018</year><volume>1</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2018.06.010</pub-id><pub-id pub-id-type="pmid">30322458</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Heppolette</surname><given-names>C. A. A.</given-names></name><name name-style="western"><surname>Brunnen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bampoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Odor</surname><given-names>P. M.</given-names></name><article-title>Clinical
Pharmacokinetics
and Pharmacodynamics of Levobupivacaine</article-title><source>Clin.
Pharmacokinet.</source><year>2020</year><volume>59</volume><issue>6</issue><fpage>715</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00868-0</pub-id><pub-id pub-id-type="pmid">32034727</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Gao</surname><given-names>Y. N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>Q. L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B. D.</given-names></name><article-title>The Anesthetic Bupivacaine Induces
Cardiotoxicity by Targeting L-Type
Voltage-Dependent Calcium Channels</article-title><source>J. Int.
Med. Res.</source><year>2020</year><volume>48</volume><issue>8</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1177/0300060520942619</pub-id><pub-id pub-id-type="pmcid">PMC7441289</pub-id><pub-id pub-id-type="pmid">32812463</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Hino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsujikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>K.</given-names></name><article-title>Left Ventricular
Hypertrophy Increases
Susceptibility to Bupivacaine-Induced Cardiotoxicity through Overexpression
of Transient Receptor Potential Canonical Channels in Rats</article-title><source>Anesthesiology</source><year>2020</year><volume>133</volume><issue>5</issue><fpage>1077</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000003554</pub-id><pub-id pub-id-type="pmid">32915958</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Papadimos</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><article-title>Apelin-13
Reverses Bupivacaine-Induced Cardiotoxicity via the Adenosine
Monophosphate-Activated Protein Kinase Pathway</article-title><source>Anesth. Analg.</source><year>2021</year><volume>133</volume><issue>4</issue><fpage>1048</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000005692</pub-id><pub-id pub-id-type="pmid">34524989</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Foster</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Markham</surname><given-names>A.</given-names></name><article-title>Levobupivacaine: A
Review of Its Pharmacology and Use
as a Local Anaesthetic</article-title><source>Drugs</source><year>2000</year><volume>59</volume><issue>3</issue><fpage>551</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.2165/00003495-200059030-00013</pub-id><pub-id pub-id-type="pmid">10776835</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>de
Ara&#250;jo</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Fraceto</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>de F&#225;tima de Assun&#231;&#227;o
Braga</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><article-title>Drug-Delivery Systems for Racemic
Bupivacaine (S50-R50) and Bupivacaine Enantiomeric Mixture (S75-R25):
Cyclodextrins Effects on Sciatic Nerve Blockade in Mice</article-title><source>Rev. Bras. Anestesiol.</source><year>2005</year><volume>55</volume><issue>3</issue><fpage>316</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1590/S0034-70942005000300008</pub-id><pub-id pub-id-type="pmid">19471836</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Graf</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bosnajak</surname><given-names>Z. J.</given-names></name><name name-style="western"><surname>Stowed</surname><given-names>D. F.</given-names></name><article-title>Stereospecific Effect
of Bupivacaine Isomers on Atrioventricular Conduction in the Isolated
Perfused Guinea Pig Heart</article-title><source>Anesthesiology</source><year>1997</year><volume>86</volume><issue>2</issue><fpage>410</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1097/00000542-199702000-00016</pub-id><pub-id pub-id-type="pmid">9054259</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Xavier
Mazoit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Decaux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouaziz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Edouard</surname><given-names>A.</given-names></name><article-title>Comparative
Ventricular Electrophysiologic Effect of Racemic Bupivacaine, Levobupivacaine,
and Ropivacaine on the Isolated Rabbit Heart</article-title><source>J. Am. Soc. Anesthesiol.</source><year>2000</year><volume>93</volume><issue>3</issue><fpage>784</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1097/00000542-200009000-00028</pub-id><pub-id pub-id-type="pmid">10969312</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Casati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Putzu</surname><given-names>M. B.</given-names></name><article-title>Bupivacaine, levobupivacaine
and ropivacaine: are they
clinically different?</article-title><source>Best Pract. Res., Clin.
Anaesthesiol.</source><year>2005</year><volume>19</volume><issue>2</issue><fpage>247</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2004.12.003</pub-id><pub-id pub-id-type="pmid">15966496</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Cereda</surname><given-names>C. M. S.</given-names></name><name name-style="western"><surname>Mecatti</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Papini</surname><given-names>J. Z. B.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Franz-Montan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>T.</given-names></name><name name-style="western"><surname>J&#250;nior</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Grillo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fraceto</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Calafatti</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Tofoli</surname><given-names>G. R.</given-names></name><article-title>Bupivacaine in Alginate and Chitosan
Nanoparticles:
An in Vivo Evaluation of Efficacy, Pharmacokinetics, and Local Toxicity</article-title><source>J. Pain Res.</source><year>2018</year><volume>11</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.2147/JPR.S158695</pub-id><pub-id pub-id-type="pmid">29670395</pub-id><pub-id pub-id-type="pmcid">PMC5896646</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Hamaji</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Rezende</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Mattar</surname><given-names>R.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Vieira</surname><given-names>J. E. D.</given-names></name><name name-style="western"><surname>Auler</surname><given-names>J. O. C.</given-names></name><article-title>Comparative
Study Related to Cardiovascular Safety
between Bupivacaine (S75-R25) and Ropivacaine in Brachial Plexus Block</article-title><source>Brazilian J. Anesthesiol.</source><year>2013</year><volume>63</volume><issue>4</issue><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.bjane.2012.06.001</pub-id><pub-id pub-id-type="pmid">24565238</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Souza</surname><given-names>M. C. O.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lanchote</surname><given-names>V. L.</given-names></name><article-title>Analysis
of Bupivacaine
Enantiomers in Plasma as Total and Unbound Concentrations Using LC-MS/MS:
Application in a Pharmacokinetic Study of a Parturient with Placental
Transfer</article-title><source>J. Pharm. Biomed. Anal.</source><year>2019</year><volume>164</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2018.10.040</pub-id><pub-id pub-id-type="pmid">30399533</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Guan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N.</given-names></name><article-title>Local Anesthetic
Bupivacaine Inhibits Melanoma Proliferation and Metastasis by Targeting
PAPSS2</article-title><source>Discovery Med.</source><year>2024</year><volume>36</volume><issue>186</issue><fpage>1499</fpage><pub-id pub-id-type="doi">10.24976/Discov.Med.202436186.139</pub-id><pub-id pub-id-type="pmid">39054720</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Chiu</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Liou</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y. S.</given-names></name><article-title>Bupivacaine Induces
Apoptosis through Caspase-Dependent
and -Independent Pathways in Canine Mammary Tumor Cells</article-title><source>Res. Vet. Sci.</source><year>2015</year><volume>100</volume><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2015.03.024</pub-id><pub-id pub-id-type="pmid">25843897</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Zuckerman</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Frames</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Mirshahidi</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Otoukesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mirshahidi</surname><given-names>S.</given-names></name><article-title>Antiproliferative
Effect of Bupivacaine
on Patient-Derived Sarcoma Cells</article-title><source>Mol. Clin
Oncol.</source><year>2020</year><volume>13</volume><issue>3</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3892/mco.2020.2077</pub-id><pub-id pub-id-type="pmid">32754321</pub-id><pub-id pub-id-type="pmcid">PMC7393627</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q. G.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H. Y.</given-names></name><article-title>Bupivacaine Induces
Reactive Oxygen Species Production via Activation of the AMP-Activated
Protein Kinase-Dependent Pathway</article-title><source>Pharmacology</source><year>2011</year><volume>87</volume><issue>3&#8211;4</issue><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1159/000323402</pub-id><pub-id pub-id-type="pmid">21304223</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Local Anesthetic
Bupivacaine Inhibits Proliferation and Metastasis of Hepatocellular
Carcinoma Cells via Suppressing PI3K/Akt and MAPK Signaling</article-title><source>J. Biochem. Mol. Toxicol.</source><year>2021</year><volume>35</volume><issue>10</issue><elocation-id>e22871&#8211;e22882</elocation-id><pub-id pub-id-type="doi">10.1002/jbt.22871</pub-id><pub-id pub-id-type="pmid">34338398</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Muller</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Shegokar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Keck</surname><given-names>C. M.</given-names></name><article-title>20 Years
of Lipid Nanoparticles (SLN
&amp; NLC): Present State of Development &amp; Industrial Applications</article-title><source>Curr. Drug Discovery Technol.</source><year>2011</year><volume>8</volume><issue>3</issue><fpage>207</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.2174/157016311796799062</pub-id><pub-id pub-id-type="pmid">21291409</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Javed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mangla</surname><given-names>B.</given-names></name><name name-style="western"><surname>Almoshari</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>W.</given-names></name><article-title>Nanostructured
Lipid Carrier System: A Compendium of Their Formulation Development
Approaches, Optimization Strategies by Quality by Design, and Recent
Applications in Drug Delivery</article-title><source>Nanotechnol.
Rev.</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>1744</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1515/ntrev-2022-0109</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Garg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pathania</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>S. V.</given-names></name><article-title>Nanostructured Lipid
Carriers: A Promising Drug Carrier for Targeting Brain Tumours</article-title><source>Futur J. Pharm. Sci.</source><year>2022</year><volume>8</volume><issue>1</issue><fpage>25</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1186/s43094-022-00414-8</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Izza</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wibisono</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kajimura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mitsuoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Umakoshi</surname><given-names>H.</given-names></name><article-title>Dependence of the Core-Shell
Structure on the Lipid Composition of Nanostructured Lipid Carriers:
Implications for Drug Carrier Design</article-title><source>ACS Appl.
Nano Mater.</source><year>2022</year><volume>5</volume><issue>7</issue><fpage>9958</fpage><lpage>9969</lpage><pub-id pub-id-type="doi">10.1021/acsanm.2c02214</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Carbone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>M. D. C.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>M. D. C.</given-names></name><name name-style="western"><surname>Martins-Gomes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Souto</surname><given-names>E. M. B.</given-names></name><name name-style="western"><surname>Musumeci</surname><given-names>T.</given-names></name><article-title>Clotrimazole-Loaded
Mediterranean Essential Oils NLC: A Synergic Treatment of Candida
Skin Infections</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><issue>5</issue><fpage>231</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics11050231</pub-id><pub-id pub-id-type="pmid">31085997</pub-id><pub-id pub-id-type="pmcid">PMC6572383</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Rodrigues
da Silva</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>L. D. D.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F. V. D.</given-names></name><name name-style="western"><surname>Geronimo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>F. F. D.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><article-title>Antineoplastics Encapsulated
in Nanostructured Lipid Carriers</article-title><source>Molecules</source><year>2021</year><volume>26</volume><issue>22</issue><fpage>6929</fpage><lpage>6953</lpage><pub-id pub-id-type="doi">10.3390/molecules26226929</pub-id><pub-id pub-id-type="pmid">34834022</pub-id><pub-id pub-id-type="pmcid">PMC8619566</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Geronimo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rodrigues da Silva</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>de Moura</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>L. N. M.</given-names></name><name name-style="western"><surname>Guilherme</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Breitkreitz</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><article-title>Development of S75: R25 Bupivacaine-Loaded Lipid Nanoparticles
Functionalized with Essential Oils for Treating Melanoma</article-title><source>J. Chem. Technol. Biotechnol.</source><year>2021</year><volume>96</volume><issue>8</issue><fpage>2197</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1002/jctb.6715</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Bia&#322;o&#324;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krzy&#347;ko-&#321;upicka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nowakowska-Bogdan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wieczorek</surname><given-names>P. P.</given-names></name><article-title>Chemical Composition of Two Different
Lavender Essential
Oils and Their Effect on Facial Skin Microbiota</article-title><source>Molecules</source><year>2019</year><volume>24</volume><issue>18</issue><fpage>3270</fpage><lpage>3286</lpage><pub-id pub-id-type="doi">10.3390/molecules24183270</pub-id><pub-id pub-id-type="pmid">31500359</pub-id><pub-id pub-id-type="pmcid">PMC6767019</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Erland</surname><given-names>L. A. E.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>S. S.</given-names></name><article-title>Lavender (Lavandula Angustifolia)
Oils</article-title><source>Essential Oils In Food Preservation, Flavor
And Safety</source><year>2016</year><volume>1</volume><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-416641-7.00057-2</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><article-title>In Vitro and in Vivo Efficacy Studies of Lavender Angustifolia Essential
Oil and Its Active Constituents on the Proliferation of Human Prostate
Cancer</article-title><source>Integr. Cancer Ther.</source><year>2017</year><volume>16</volume><issue>2</issue><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1177/1534735416645408</pub-id><pub-id pub-id-type="pmid">27151584</pub-id><pub-id pub-id-type="pmcid">PMC5739122</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Aboalhaija</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Syaj</surname><given-names>H.</given-names></name><name name-style="western"><surname>Afifi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sunoqrot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Shalabi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Talib</surname><given-names>W.</given-names></name><article-title>Chemical Evaluation,
In Vitro and In Vivo Anticancer Activity of
Lavandula Angustifolia Grown in Jordan</article-title><source>Molecules</source><year>2022</year><volume>27</volume><issue>18</issue><fpage>5910</fpage><lpage>5921</lpage><pub-id pub-id-type="doi">10.3390/molecules27185910</pub-id><pub-id pub-id-type="pmid">36144646</pub-id><pub-id pub-id-type="pmcid">PMC9505037</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Peng</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>S.-T.</given-names></name><article-title>The Melanogenesis
Alteration Effects of Achillea Millefolium L. Essential Oil and Linalyl
Acetate: Involvement of Oxidative Stress and the JNK and ERK Signaling
Pathways in Melanoma Cells</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>4</issue><elocation-id>e95186&#8211;e95194</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0095186</pub-id><pub-id pub-id-type="pmid">24743745</pub-id><pub-id pub-id-type="pmcid">PMC3990609</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Slominski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zbytek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Slominski</surname><given-names>R.</given-names></name><article-title>Inhibitors
of Melanogenesis Increase
Toxicity of Cyclophosphamide and Lymphocytes against Melanoma Cells</article-title><source>Int. J. Cancer</source><year>2009</year><volume>124</volume><issue>6</issue><fpage>1470</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1002/ijc.24005</pub-id><pub-id pub-id-type="pmid">19085934</pub-id><pub-id pub-id-type="pmcid">PMC2628959</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Slominski</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Sarna</surname><given-names>T.</given-names></name><name name-style="western"><surname>P&#322;onka</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bro&#380;yna</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Slominski</surname><given-names>A. T. M.</given-names></name><article-title>Melanin,
and Melanogenesis: The Yin and Yang Relationship</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>842496</fpage><lpage>842513</lpage><pub-id pub-id-type="doi">10.3389/fonc.2022.842496</pub-id><pub-id pub-id-type="pmid">35359389</pub-id><pub-id pub-id-type="pmcid">PMC8963986</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Ovidi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Masci</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Taddei</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Paolicelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petralito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trilli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mastrogiovanni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tiezzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casadei</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Giacomello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garzoli</surname><given-names>S.</given-names></name><article-title>Chemical Investigation and Screening of Anti-Proliferative
Activity on Human Cell Lines of Pure and Nano-Formulated Lavandin
Essential Oil</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><issue>11</issue><fpage>352</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.3390/ph13110352</pub-id><pub-id pub-id-type="pmid">33138099</pub-id><pub-id pub-id-type="pmcid">PMC7692866</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Xing</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W. A.</given-names></name><article-title>Lidocaine Induces
Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma
Cells in Vitro and in a Xenograft Model in Vivo</article-title><source>Anesthesiology</source><year>2017</year><volume>126</volume><issue>5</issue><fpage>868</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000001528</pub-id><pub-id pub-id-type="pmid">28121635</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><article-title>Lidocaine
Inhibits
Melanoma Cell Proliferation by Regulating ERK Phosphorylation</article-title><source>J. Cell. Biochem.</source><year>2019</year><volume>120</volume><issue>4</issue><fpage>6402</fpage><lpage>6408</lpage><pub-id pub-id-type="doi">10.1002/jcb.27927</pub-id><pub-id pub-id-type="pmid">30430626</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><article-title>Clinically
Relevant Concentrations of Lidocaine Inhibit
Tumor Angiogenesis through Suppressing VEGF/VEGFR2 Signaling</article-title><source>Cancer Chemother. Pharmacol.</source><year>2019</year><volume>83</volume><issue>6</issue><fpage>1007</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1007/s00280-019-03815-4</pub-id><pub-id pub-id-type="pmid">30887179</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><article-title>Combination Therapy
with Ropivacaine-Loaded Liposomes
and Nutrient Deprivation for Simultaneous Cancer Therapy and Cancer
Pain Relief</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>11</issue><fpage>4885</fpage><lpage>4899</lpage><pub-id pub-id-type="doi">10.7150/thno.43932</pub-id><pub-id pub-id-type="pmid">32308756</pub-id><pub-id pub-id-type="pmcid">PMC7163441</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><article-title>Tetracaine
Hydrochloride
Induces Cell Cycle Arrest in Melanoma by Downregulating HnRNPA1</article-title><source>Toxicol. Appl. Pharmacol.</source><year>2022</year><volume>434</volume><fpage>115810</fpage><lpage>115822</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2021.115810</pub-id><pub-id pub-id-type="pmid">34822839</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>F.</given-names></name><article-title>Enhanced Antitumor
Activity of Lidocaine
Nanoparticles Encapsulated by a Self-Assembling Peptide</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>770892</fpage><lpage>770903</lpage><pub-id pub-id-type="doi">10.3389/fphar.2022.770892</pub-id><pub-id pub-id-type="pmid">35529446</pub-id><pub-id pub-id-type="pmcid">PMC9068872</pub-id></element-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Tibensky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blasko</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vargovic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jakubikova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cholujova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jakubechova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mravec</surname><given-names>B.</given-names></name><article-title>Topical Application
of Local Anesthetics to Melanoma Increases the Efficacy of Anti-PD-1
Therapy</article-title><source>Neoplasma</source><year>2023</year><volume>70</volume><issue>3</issue><fpage>375</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.4149/neo_2023_230418N216</pub-id><pub-id pub-id-type="pmid">37498073</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kagota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shinozuka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kunitomo</surname><given-names>M.</given-names></name><article-title>Characterization of Mouse Melanoma Cell Lines by Their
Mortal Malignancy Using an Experimental Metastatic Model</article-title><source>Life Sci.</source><year>2002</year><volume>70</volume><issue>7</issue><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(01)01454-0</pub-id><pub-id pub-id-type="pmid">11833741</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Khayyati
Kohnehshahri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarkesh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohamed Khosroshahi</surname><given-names>L.</given-names></name><name name-style="western"><surname>HajiEsmailpoor</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Aghebati-Maleki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name><article-title>Current Status
of Skin Cancers with a Focus on Immunology and Immunotherapy</article-title><source>Cancer Cell Int.</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>174</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1186/s12935-023-03012-7</pub-id><pub-id pub-id-type="pmid">37605149</pub-id><pub-id pub-id-type="pmcid">PMC10440946</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Betz-Stablein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soyer</surname><given-names>H. P.</given-names></name><article-title>Overdiagnosis in
Melanoma Screening: Is It a Real Problem?</article-title><source>Dermatol.
Pract. Concept.</source><year>2023</year><volume>13</volume><issue>4</issue><elocation-id>e2023247&#8211;e2023249</elocation-id><pub-id pub-id-type="doi">10.5826/dpc.1304a247</pub-id><pub-id pub-id-type="pmid">37992381</pub-id><pub-id pub-id-type="pmcid">PMC10656178</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><article-title>Anesthesia-Related
Intervention for Long-Term Survival and Cancer Recurrence Following
Breast Cancer Surgery: A Systematic Review of Prospective Studies</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><elocation-id>e0296158&#8211;e0296167</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0296158</pub-id><pub-id pub-id-type="pmid">38127958</pub-id><pub-id pub-id-type="pmcid">PMC10734918</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Souto</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Baldim</surname><given-names>I.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>W. P.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gama</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Mahant</surname><given-names>S.</given-names></name><article-title>SLN and NLC for Topical,
Dermal,
and Transdermal Drug Delivery</article-title><source>Expert Opin.
Drug Delivery</source><year>2020</year><volume>1</volume><fpage>357</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1080/17425247.2020.1727883</pub-id><pub-id pub-id-type="pmid">32064958</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Overwijk</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N. P.</given-names></name><article-title>B16 as a Mouse Model
for Human Melanoma</article-title><source>Curr. Protoc. Immunol.</source><year>2000</year><volume>39</volume><issue>1</issue><fpage>20.1.1</fpage><lpage>20.1.29</lpage><pub-id pub-id-type="doi">10.1002/0471142735.im2001s39</pub-id><pub-id pub-id-type="pmcid">PMC2763508</pub-id><pub-id pub-id-type="pmid">18432774</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Erdo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karvaly</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><article-title>Critical Evaluation
and Methodological Positioning of the Transdermal
Microdialysis Technique. A Review</article-title><source>J. Controlled
Release</source><year>2016</year><volume>1</volume><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.05.035</pub-id><pub-id pub-id-type="pmid">27196741</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M.</given-names></name><article-title>Microdialysis
as an Important Technique in Systems Pharmacology&#58872;a Historical
and Methodological Review</article-title><source>Aaps J.</source><year>2017</year><volume>19</volume><issue>5</issue><fpage>1294</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1208/s12248-017-0108-2</pub-id><pub-id pub-id-type="pmid">28762127</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Slimano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Djerada</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bellouch</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Brassart-Pasco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dukic</surname><given-names>S.</given-names></name><article-title>Intratumoral Distribution of YSNSG Cyclopeptide in a Mouse Melanoma
Model Using Microdialysis</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>143</volume><fpage>102501</fpage><lpage>1025047</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.105201</pub-id><pub-id pub-id-type="pmid">31866565</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Pigatto</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>de Araujo</surname><given-names>B. V.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>B. G. S.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dalla Costa</surname><given-names>T.</given-names></name><article-title>Population
Pharmacokinetic Modeling of Etoposide Free
Concentrations in Solid Tumor</article-title><source>Pharm. Res.</source><year>2016</year><volume>33</volume><issue>7</issue><fpage>1657</fpage><lpage>1670</lpage><pub-id pub-id-type="doi">10.1007/s11095-016-1906-4</pub-id><pub-id pub-id-type="pmid">27068281</pub-id></element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Isteni&#269;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cvetko</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zabret</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stopar Pintari&#269;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Umek</surname><given-names>N.</given-names></name><article-title>Determination of Bupivacaine Tissue Concentration in Human Biopsy
Samples Using High-performance Liquid Chromatography with Mass Spectrometry</article-title><source>Biomed. Chromatogr.</source><year>2021</year><volume>35</volume><issue>11</issue><elocation-id>e5198&#8211;e5208</elocation-id><pub-id pub-id-type="doi">10.1002/bmc.5198</pub-id><pub-id pub-id-type="pmid">34121212</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>dos
Santos</surname><given-names>M. S. C.</given-names></name><name name-style="western"><surname>Gouv&#234;a</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>de Moura</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Paterno</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>P. E. N.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Damasceno</surname><given-names>E. A. M.</given-names></name><name name-style="western"><surname>Veiga-Souza</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>de Azevedo</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>B&#225;o</surname><given-names>S. N.</given-names></name><article-title>Nanographene Oxide-Methylene Blue as Phototherapies
Platform for Breast Tumor Ablation and Metastasis Prevention in a
Syngeneic Orthotopic Murine Model</article-title><source>J. Nanobiotechnol.</source><year>2018</year><volume>16</volume><issue>1</issue><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1186/s12951-018-0333-6</pub-id><pub-id pub-id-type="pmcid">PMC5789561</pub-id><pub-id pub-id-type="pmid">29382332</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Domingues</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>P.</given-names></name><name name-style="western"><surname>Populo</surname><given-names>H.</given-names></name><article-title>Melanoma Treatment
in Review</article-title><source>ImmunoTargets Ther.</source><year>2018</year><volume>7</volume><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.2147/ITT.S134842</pub-id><pub-id pub-id-type="pmid">29922629</pub-id><pub-id pub-id-type="pmcid">PMC5995433</pub-id></element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Bouchereau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaplain</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fort</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beauchet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sidib&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chapalain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez-Lara</surname><given-names>L.</given-names></name><name name-style="western"><surname>Longvert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saiag</surname><given-names>P.</given-names></name><name name-style="western"><surname>Funck-Brentano</surname><given-names>E.</given-names></name><article-title>Impact of Prior Treatment with Immune
Checkpoint Inhibitors on Dacarbazine Efficacy in Metastatic Melanoma</article-title><source>Br. J. Cancer</source><year>2021</year><volume>125</volume><issue>7</issue><fpage>948</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01486-8</pub-id><pub-id pub-id-type="pmid">34262147</pub-id><pub-id pub-id-type="pmcid">PMC8476529</pub-id></element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Zhang</surname><given-names>X. H.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>E. Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H. Q.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X. M.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y. H.</given-names></name><article-title>Efficacy
of Combined Axitinib with
Dacarbazine in a B16F1Melanoma Xenograft Model</article-title><source>Oncol. Lett.</source><year>2013</year><volume>6</volume><issue>1</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1345</pub-id><pub-id pub-id-type="pmid">23946779</pub-id><pub-id pub-id-type="pmcid">PMC3742768</pub-id></element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Durst</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Arras</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palme</surname><given-names>R.</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Jirkof</surname><given-names>P.</given-names></name><article-title>Lidocaine
and Bupivacaine as Part of Multimodal Pain Management in a C57BL/6J
Laparotomy Mouse Model</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>10918</fpage><lpage>10934</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-90331-2</pub-id><pub-id pub-id-type="pmid">34035397</pub-id><pub-id pub-id-type="pmcid">PMC8149411</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Hewitson</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Wigg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>G. J.</given-names></name><article-title>Tissue Preparation for Histochemistry:
Fixation, Embedding, and Antigen Retrieval for Light Microscopy</article-title><source>Methods Mol. Biol.</source><year>2010</year><volume>611</volume><fpage>3</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-345-9_1</pub-id><pub-id pub-id-type="pmid">19960318</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Clark</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>From</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bernardino</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Mihm</surname><given-names>M. C.</given-names></name><article-title>The Histogenesis
and Biologic Behavior of Primary Human Malignant Melanomas of the
Skin</article-title><source>Cancer Res.</source><year>1969</year><volume>29</volume><issue>3</issue><fpage>705</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">5773814</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Scolyer</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G. V.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J. F.</given-names></name><article-title>Evolving
Concepts in Melanoma Classification
and Their Relevance to Multidisciplinary Melanoma Patient Care</article-title><source>Mol. Oncol.</source><year>2011</year><volume>5</volume><issue>2</issue><fpage>124</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2011.03.002</pub-id><pub-id pub-id-type="pmid">21482206</pub-id><pub-id pub-id-type="pmcid">PMC5528281</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Tas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Erturk</surname><given-names>K.</given-names></name><article-title>Presence of Histological Regression as a Prognostic
Factor in Cutaneous Melanoma Patients</article-title><source>Melanoma
Res.</source><year>2016</year><volume>26</volume><issue>5</issue><fpage>492</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000277</pub-id><pub-id pub-id-type="pmid">27380112</pub-id></element-citation></ref><ref id="ref78"><element-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Verma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cowperthwaite</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Markey</surname><given-names>M. K.</given-names></name><article-title>Differentiating
Tumor Recurrence from Treatment Necrosis: A Review of Neuro-Oncologic
Imaging Strategies</article-title><source>Neuro-Oncol.</source><year>2013</year><volume>15</volume><issue>5</issue><fpage>515</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nos307</pub-id><pub-id pub-id-type="pmid">23325863</pub-id><pub-id pub-id-type="pmcid">PMC3635510</pub-id></element-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Carlsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gullberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hafstr&#246;m</surname><given-names>L.</given-names></name><article-title>Estimation
of Liver Tumor Volume
Using Different Formulas?An Experimental Study in Rats</article-title><source>J. Cancer Res. Clin Oncol.</source><year>1983</year><volume>105</volume><issue>1</issue><fpage>20</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/BF00391826</pub-id><pub-id pub-id-type="pmid">6833336</pub-id></element-citation></ref><ref id="ref80"><element-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Vakkila</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lotze</surname><given-names>M. T.</given-names></name><article-title>Inflammation and
Necrosis Promote Tumour Growth</article-title><source>Nat. Rev. Immunol.</source><year>2004</year><volume>4</volume><issue>8</issue><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/nri1415</pub-id><pub-id pub-id-type="pmid">15286730</pub-id></element-citation></ref><ref id="ref81"><element-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Ladstein</surname><given-names>R.
G.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Straume</surname><given-names>O.</given-names></name><name name-style="western"><surname>Akslen</surname><given-names>L. A.</given-names></name><article-title>Tumor Necrosis Is
a Prognostic Factor in Thick Cutaneous Melanoma</article-title><source>Am. J. Surg. Pathol.</source><year>2012</year><volume>36</volume><issue>10</issue><fpage>1477</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31825a5b45</pub-id><pub-id pub-id-type="pmid">22982891</pub-id></element-citation></ref><ref id="ref82"><element-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Ruiter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bogenrieder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Herlyn</surname><given-names>M.</given-names></name><article-title>Melanoma&#8211;Stroma
Interactions: Structural and Functional Aspects</article-title><source>Lancet Oncol.</source><year>2002</year><volume>3</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(01)00620-9</pub-id><pub-id pub-id-type="pmid">11905603</pub-id></element-citation></ref><ref id="ref83"><element-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Chandler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Buckanovich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>L. G.</given-names></name><article-title>The Double Edge Sword of Fibrosis
in Cancer</article-title><source>Transl. Res.</source><year>2019</year><volume>209</volume><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2019.02.006</pub-id><pub-id pub-id-type="pmid">30871956</pub-id><pub-id pub-id-type="pmcid">PMC6545239</pub-id></element-citation></ref><ref id="ref84"><element-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Bland</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>D. G.</given-names></name><article-title>Statistics Notes:
Survival Probabilities (the Kaplan-Meier
Method)</article-title><source>BMJ</source><year>1998</year><volume>317</volume><issue>7172</issue><fpage>1572</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1136/bmj.317.7172.1572</pub-id><pub-id pub-id-type="pmid">9836663</pub-id><pub-id pub-id-type="pmcid">PMC1114388</pub-id></element-citation></ref><ref id="ref85"><element-citation publication-type="journal" id="cit85"><name name-style="western"><surname>da
Silva</surname><given-names>G. H. R.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>L. N. M.</given-names></name><name name-style="western"><surname>Mitsutake</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guilherme</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Poppi</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Breitkreitz</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><article-title>A Nanotechnological Approach to Improve the Anaesthetic
Effect of Bupivacaine</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>529</volume><issue>1&#8211;2</issue><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.06.066</pub-id><pub-id pub-id-type="pmid">28655546</pub-id></element-citation></ref><ref id="ref86"><element-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Dobreva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stefanov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andonova</surname><given-names>V.</given-names></name><article-title>Natural Lipids
as Structural Components
of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for
Topical Delivery</article-title><source>Curr. Pharm. Des.</source><year>2020</year><volume>26</volume><issue>36</issue><fpage>4524</fpage><lpage>4535</lpage><pub-id pub-id-type="doi">10.2174/1381612826666200514221649</pub-id><pub-id pub-id-type="pmid">32410552</pub-id></element-citation></ref><ref id="ref87"><element-citation publication-type="journal" id="cit87"><name name-style="western"><surname>Ghasemiyeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mohammadi-Samani</surname><given-names>S.</given-names></name><article-title>Solid Lipid Nanoparticles and Nanostructured Lipid
Carriers as Novel Drug Delivery Systems: Applications, Advantages
and Disadvantages</article-title><source>Res. Pharm. Sci.</source><year>2018</year><volume>13</volume><issue>4</issue><fpage>288</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.4103/1735-5362.235156</pub-id><pub-id pub-id-type="pmid">30065762</pub-id><pub-id pub-id-type="pmcid">PMC6040163</pub-id></element-citation></ref><ref id="ref88"><element-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Danaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dehghankhold</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ataei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hasanzadeh Davarani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Javanmard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dokhani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khorasani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mozafari</surname><given-names>M.</given-names></name><article-title>Impact of Particle
Size and Polydispersity Index on
the Clinical Applications of Lipidic Nanocarrier Systems</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><issue>2</issue><fpage>57</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics10020057</pub-id><pub-id pub-id-type="pmid">29783687</pub-id><pub-id pub-id-type="pmcid">PMC6027495</pub-id></element-citation></ref><ref id="ref89"><element-citation publication-type="journal" id="cit89"><name name-style="western"><surname>Carvalho</surname><given-names>F. V. D.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>L. N. D. M.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>L. D. D.</given-names></name><name name-style="western"><surname>Rodrigues
da Silva</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Mitsutake</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Geronimo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Breitkreitz</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name><article-title>Docetaxel Loaded in
Copaiba Oil-Nanostructured Lipid Carriers as a Promising DDS for Breast
Cancer Treatment</article-title><source>Molecules</source><year>2022</year><volume>27</volume><issue>24</issue><fpage>8838</fpage><lpage>8855</lpage><pub-id pub-id-type="doi">10.3390/molecules27248838</pub-id><pub-id pub-id-type="pmid">36557969</pub-id><pub-id pub-id-type="pmcid">PMC9788038</pub-id></element-citation></ref><ref id="ref90"><element-citation publication-type="journal" id="cit90"><name name-style="western"><surname>Nguyen</surname><given-names>L. N. M.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z. P.</given-names></name><name name-style="western"><surname>Sindhwani</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mladjenovic</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W. C. W.</given-names></name><article-title>The Mechanisms
of Nanoparticle Delivery to Solid Tumours</article-title><source>Nat.
Rev. Bioeng.</source><year>2024</year><volume>2</volume><issue>3</issue><fpage>201</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1038/s44222-024-00154-9</pub-id></element-citation></ref><ref id="ref91"><element-citation publication-type="journal" id="cit91"><name name-style="western"><surname>M&#252;ller</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>J. S. H.</given-names></name><name name-style="western"><surname>Piegeler</surname><given-names>T.</given-names></name><article-title>Local Anesthetics and
Recurrence
after Cancer Surgery-What&#8217;s New? A Narrative Review</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><issue>4</issue><fpage>719</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.3390/jcm10040719</pub-id><pub-id pub-id-type="pmid">33670434</pub-id><pub-id pub-id-type="pmcid">PMC7918400</pub-id></element-citation></ref><ref id="ref92"><element-citation publication-type="journal" id="cit92"><name name-style="western"><surname>Monterrubio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olaciregui</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Pascual-Pasto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vila-Ubach</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuadrado-Vilanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferrandiz</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Castillo-Ecija</surname><given-names>H.</given-names></name><name name-style="western"><surname>Glisoni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuplennik</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jungbluth</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Torres</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lavarino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>N. K. V.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sosnik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carcaboso</surname><given-names>A. M.</given-names></name><article-title>Targeted
Drug Distribution in Tumor Extracellular Fluid of GD2-Expressing Neuroblastoma
Patient-Derived Xenografts Using SN-38-Loaded Nanoparticles Conjugated
to the Monoclonal Antibody 3F8</article-title><source>J. Controlled
Release</source><year>2017</year><volume>255</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.04.016</pub-id><pub-id pub-id-type="pmcid">PMC5564453</pub-id><pub-id pub-id-type="pmid">28412222</pub-id></element-citation></ref><ref id="ref93"><element-citation publication-type="journal" id="cit93"><name name-style="western"><surname>Ernsting</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S. D.</given-names></name><article-title>Factors Controlling
the Pharmacokinetics, Biodistribution and Intratumoral Penetration
of Nanoparticles</article-title><source>J. Controlled Release</source><year>2013</year><volume>172</volume><issue>3</issue><fpage>782</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.09.013</pub-id><pub-id pub-id-type="pmcid">PMC3891171</pub-id><pub-id pub-id-type="pmid">24075927</pub-id></element-citation></ref><ref id="ref94"><element-citation publication-type="journal" id="cit94"><name name-style="western"><surname>Nguyen</surname><given-names>L. N. M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z. P.</given-names></name><name name-style="western"><surname>Sindhwani</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mladjenovic</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Stordy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W. C. W.</given-names></name><article-title>The
Exit of Nanoparticles from Solid Tumours</article-title><source>Nat.
Mater.</source><year>2023</year><volume>22</volume><issue>10</issue><fpage>1261</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1038/s41563-023-01630-0</pub-id><pub-id pub-id-type="pmid">37592029</pub-id></element-citation></ref><ref id="ref95"><element-citation publication-type="journal" id="cit95"><name name-style="western"><surname>Tayarani-Najaran</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Amiri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Emami</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Asili</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>S. H.</given-names></name><article-title>Comparative Studies of Cytotoxic
and Apoptotic Properties
of Different Extracts and the Essential Oil of Lavandula Angustifolia
on Malignant and Normal Cells</article-title><source>Nutr. Cancer</source><year>2014</year><volume>66</volume><issue>3</issue><fpage>424</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1080/01635581.2013.878736</pub-id><pub-id pub-id-type="pmid">24571090</pub-id></element-citation></ref><ref id="ref96"><element-citation publication-type="journal" id="cit96"><name name-style="western"><surname>Valcourt</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Kapadia</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Scully</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Day</surname><given-names>E. S.</given-names></name><article-title>Best Practices
for Preclinical In Vivo Testing of Cancer Nanomedicines</article-title><source>Adv. Healthcare Mater.</source><year>2020</year><volume>9</volume><issue>12</issue><elocation-id>e2000110&#8211;e2000139</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202000110</pub-id><pub-id pub-id-type="pmcid">PMC7473451</pub-id><pub-id pub-id-type="pmid">32367687</pub-id></element-citation></ref><ref id="ref97"><element-citation publication-type="journal" id="cit97"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwendeman</surname><given-names>A.</given-names></name><article-title>Survey of
Clinical Translation of Cancer Nanomedicines&#58872;Lessons Learned
from Successes and Failures</article-title><source>Acc. Chem. Res.</source><year>2019</year><volume>52</volume><issue>9</issue><fpage>2445</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.9b00228</pub-id><pub-id pub-id-type="pmid">31424909</pub-id></element-citation></ref><ref id="ref98"><element-citation publication-type="journal" id="cit98"><name name-style="western"><surname>Fearon</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Hustead</surname><given-names>D. S.</given-names></name><article-title>Definition of Cancer Cachexia: Effect
of Weight Loss, Reduced Food Intake, and Systemic Inflammation on
Functional Status and Prognosis</article-title><source>Am. J. Clin.
Nutr.</source><year>2006</year><volume>83</volume><issue>6</issue><fpage>1345</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1093/ajcn/83.6.1345</pub-id><pub-id pub-id-type="pmid">16762946</pub-id></element-citation></ref><ref id="ref99"><element-citation publication-type="journal" id="cit99"><name name-style="western"><surname>Muscaritoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arends</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baracos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barthelemy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bozzetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>H&#252;tterer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Isenring</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaasa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krznaric</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Laird</surname><given-names>B.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laviano</surname><given-names>A.</given-names></name><name name-style="western"><surname>M&#252;hlebach</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oldervoll</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ravasco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Solheim</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>F.</given-names></name><name name-style="western"><surname>de van der Schueren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>S. C.</given-names></name><article-title>ESPEN Practical
Guideline: Clinical Nutrition in Cancer</article-title><source>Clin
Nutr.</source><year>2021</year><volume>40</volume><issue>5</issue><fpage>2898</fpage><lpage>2913</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2021.02.005</pub-id><pub-id pub-id-type="pmid">33946039</pub-id></element-citation></ref><ref id="ref100"><element-citation publication-type="journal" id="cit100"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>G. K.</given-names></name><article-title>Effect of Sex and Age on Serum Biochemical
Reference Ranges in C57BL/6J Mice</article-title><source>Comp. Med.</source><year>2004</year><volume>54</volume><issue>2</issue><fpage>176</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">15134363</pub-id></element-citation></ref><ref id="ref101"><element-citation publication-type="journal" id="cit101"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hatzakis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>A. D.</given-names></name><article-title>NMR-Based
Metabolomics and Its Application in Drug Metabolism and Cancer Research</article-title><source>Curr. Pharmacol. Reports</source><year>2016</year><volume>2</volume><issue>5</issue><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1007/s40495-016-0067-9</pub-id></element-citation></ref><ref id="ref102"><element-citation publication-type="journal" id="cit102"><name name-style="western"><surname>Gurcan</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Boucheron</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Can</surname><given-names>A.</given-names></name><name name-style="western"><surname>Madabhushi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rajpoot</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Yener</surname><given-names>B.</given-names></name><article-title>Histopathological Image
Analysis:
A Review</article-title><source>IEEE Rev. Biomed. Eng.</source><year>2009</year><volume>2</volume><fpage>147</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1109/RBME.2009.2034865</pub-id><pub-id pub-id-type="pmid">20671804</pub-id><pub-id pub-id-type="pmcid">PMC2910932</pub-id></element-citation></ref><ref id="ref103"><element-citation publication-type="journal" id="cit103"><name name-style="western"><surname>McGill</surname><given-names>M. R.</given-names></name><article-title>The Past and Present of Serum Aminotransferases
and
the Future of Liver Injury Biomarkers</article-title><source>Excli
J.</source><year>2016</year><volume>15</volume><fpage>817</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.17179/excli2016-800</pub-id><pub-id pub-id-type="pmid">28337112</pub-id><pub-id pub-id-type="pmcid">PMC5318690</pub-id></element-citation></ref><ref id="ref104"><element-citation publication-type="journal" id="cit104"><name name-style="western"><surname>Yadav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jangra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><article-title>Current Advancement
in Biosensing Techniques for Determination of Alanine Aminotransferase
and Aspartate Aminotransferase-a Mini Review</article-title><source>Process Biochem.</source><year>2022</year><volume>114</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.procbio.2022.01.010</pub-id></element-citation></ref><ref id="ref105"><element-citation publication-type="journal" id="cit105"><name name-style="western"><surname>Baum</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dichoso</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Carlton</surname><given-names>C. E.</given-names></name><article-title>Blood Urea Nitrogen
and Serum Creatinine</article-title><source>Urology</source><year>1975</year><volume>5</volume><issue>5</issue><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/0090-4295(75)90105-3</pub-id><pub-id pub-id-type="pmid">1093306</pub-id></element-citation></ref><ref id="ref106"><element-citation publication-type="journal" id="cit106"><name name-style="western"><surname>Kazory</surname><given-names>A.</given-names></name><article-title>Emergence of Blood Urea Nitrogen
as a Biomarker of
Neurohormonal Activation in Heart Failure</article-title><source>Am.
J. Cardiol.</source><year>2010</year><volume>106</volume><issue>5</issue><fpage>694</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2010.04.024</pub-id><pub-id pub-id-type="pmid">20723648</pub-id></element-citation></ref><ref id="ref107"><element-citation publication-type="journal" id="cit107"><name name-style="western"><surname>Matsue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Damman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Metra</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Ponikowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Teerlink</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Davison</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cleland</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Givertz</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Bloomfield</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Dittrich</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Gansevoort</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>S. J. L.</given-names></name><name name-style="western"><surname>van
der Harst</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hillege</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>van Veldhuisen</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Voors</surname><given-names>A. A.</given-names></name><article-title>Blood Urea Nitrogen-to-Creatinine Ratio in the General
Population and in Patients with Acute Heart Failure</article-title><source>Heart</source><year>2017</year><volume>103</volume><issue>6</issue><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2016-310112</pub-id><pub-id pub-id-type="pmid">27658757</pub-id></element-citation></ref><ref id="ref108"><element-citation publication-type="journal" id="cit108"><name name-style="western"><surname>Chang</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Liou</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Su</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>F. Y.</given-names></name><article-title>Creatine Kinase (CK)-MB-to-Total-CK Ratio: A Laboratory
Indicator for Primary Cancer Screening</article-title><source>Asian
Pacific J. Cancer Prev.</source><year>2015</year><volume>16</volume><issue>15</issue><fpage>6599</fpage><lpage>6603</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2015.16.15.6599</pub-id><pub-id pub-id-type="pmid">26434881</pub-id></element-citation></ref><ref id="ref109"><element-citation publication-type="journal" id="cit109"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>I. A.</given-names></name><article-title>The Clinical Utility
of CK-MB Measurement in Patients
Suspected of Acute Coronary Syndrome</article-title><source>Clin.
Chim. Acta</source><year>2016</year><volume>456</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2016.02.030</pub-id><pub-id pub-id-type="pmid">26945601</pub-id></element-citation></ref><ref id="ref110"><element-citation publication-type="journal" id="cit110"><name name-style="western"><surname>Binaghi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Congia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cossa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Massidda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pasqualucci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pilo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Serra</surname><given-names>E.</given-names></name><name name-style="western"><surname>Angelucci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Porcu</surname><given-names>M.</given-names></name><article-title>Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy
in a Patient with Hodgkin Lymphoma: An Unusual Event</article-title><source>Cardiol</source><year>2018</year><volume>139</volume><issue>1</issue><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1159/000480291</pub-id><pub-id pub-id-type="pmid">29041005</pub-id></element-citation></ref><ref id="ref111"><element-citation publication-type="journal" id="cit111"><name name-style="western"><surname>Lewis</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Lilly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K. L.</given-names></name><article-title>Lymphoma: Diagnosis
and Treatment</article-title><source>Am. Fam. Phys.</source><year>2020</year><volume>101</volume><issue>1</issue><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">31894937</pub-id></element-citation></ref><ref id="ref112"><element-citation publication-type="journal" id="cit112"><name name-style="western"><surname>Zhang</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y. B.</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>Y.</given-names></name><article-title>Preparation of Isoliquiritigenin-Loaded
Nanostructured Lipid Carrier
and the in Vivo Evaluation in Tumor-Bearing Mice</article-title><source>Eur. J. Pharm. Sci.</source><year>2013</year><volume>49</volume><issue>3</issue><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2013.04.020</pub-id><pub-id pub-id-type="pmid">23624327</pub-id></element-citation></ref><ref id="ref113"><element-citation publication-type="journal" id="cit113"><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Isern</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J. Z.</given-names></name><article-title>Studies
of Secondary Melanoma on C57BL/6J Mouse Liver Using 1H NMR Metabolomics</article-title><source>Metabolites</source><year>2013</year><volume>3</volume><issue>4</issue><fpage>1011</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.3390/metabo3041011</pub-id><pub-id pub-id-type="pmid">24958263</pub-id><pub-id pub-id-type="pmcid">PMC3937829</pub-id></element-citation></ref><ref id="ref114"><element-citation publication-type="journal" id="cit114"><name name-style="western"><surname>Thapa</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Walia</surname><given-names>A.</given-names></name><article-title>Liver Function Tests
and Their Interpretation</article-title><source>Indian J. Pediatr.</source><year>2007</year><volume>74</volume><issue>7</issue><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1007/s12098-007-0118-7</pub-id><pub-id pub-id-type="pmid">17699976</pub-id></element-citation></ref><ref id="ref115"><element-citation publication-type="journal" id="cit115"><name name-style="western"><surname>Almazroo</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Miah</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Venkataramanan</surname><given-names>R.</given-names></name><article-title>Drug Metabolism
in the Liver</article-title><source>Clin. Liver Dis.</source><year>2017</year><volume>21</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2016.08.001</pub-id><pub-id pub-id-type="pmid">27842765</pub-id></element-citation></ref><ref id="ref116"><element-citation publication-type="journal" id="cit116"><name name-style="western"><surname>Shakartalla</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Ashmawy</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Semreen</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Fayed</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al Shareef</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Jayakumar</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hamdy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>S. S. M.</given-names></name><article-title>1H-NMR
Metabolomics Analysis Identifies
Hypoxanthine as a Novel Metastasis-Associated Metabolite in Breast
Cancer</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>253</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41598-023-50866-y</pub-id><pub-id pub-id-type="pmid">38167685</pub-id><pub-id pub-id-type="pmcid">PMC10762038</pub-id></element-citation></ref><ref id="ref117"><element-citation publication-type="journal" id="cit117"><name name-style="western"><surname>Augustin</surname><given-names>N. B. F.</given-names></name><name name-style="western"><surname>Biteghe</surname><given-names>F. N.</given-names></name><name name-style="western"><surname>Padayachee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Davids</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Chalomie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ndong</surname><given-names>J. D. L. C.</given-names></name><name name-style="western"><surname>Barth</surname><given-names>S.</given-names></name><article-title>Desensitization of Metastatic Melanoma Cells to Therapeutic Treatment
through Repeated Exposure to Dacarbazine</article-title><source>J.
Photochem. Photobiol. B Biol.</source><year>2020</year><fpage>211</fpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2020.111982</pub-id><pub-id pub-id-type="pmid">32866820</pub-id></element-citation></ref><ref id="ref118"><element-citation publication-type="journal" id="cit118"><name name-style="western"><surname>Kang</surname><given-names>D.-K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.-Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.-L.</given-names></name><article-title>Cytotoxic
Effects
of Local Anesthesia through Lidocaine/Ropivacaine on Human Melanoma
Cell Lines</article-title><source>Brazilian J. Anesthesiol.</source><year>2016</year><volume>66</volume><issue>6</issue><fpage>594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.bjane.2015.04.002</pub-id><pub-id pub-id-type="pmid">27793234</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>